[{"id":340973,"date":"2024-12-13T16:50:18","date_gmt":"2024-12-13T16:50:18","guid":{"rendered":"https:\/\/pharmaceutical-journal.com\/?post_type=news&p=340973"},"modified":"2024-12-13T16:50:20","modified_gmt":"2024-12-13T16:50:20","slug":"royal-pharmaceutical-society-membership-fees-2025","status":"publish","type":"news","link":"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025","title":{"rendered":"Royal Pharmaceutical Society membership fees 2025"},"content":{"rendered":"<p>The Royal Pharmaceutical Society Assembly has announced membership fees for 2025. The annual membership subscriptions are detailed in the table below. <\/p><div class=\"flourish-embed flourish-table\" data-src=\"visualisation\/20779964?1253504\"><script src=\"https:\/\/public.flourish.studio\/resources\/embed.js\"><\/script><noscript><img decoding=\"async\" src=\"https:\/\/public.flourish.studio\/visualisation\/20779964\/thumbnail\" width=\"100%\" alt=\"table visualization\" \/><\/noscript><\/div>","protected":false},"excerpt":{"rendered":"<p>The Royal Pharmaceutical Society Assembly has announced membership fees for 2025. The annual membership subscriptions are detailed in the table below. <\/p>\n","protected":false},"featured_media":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"content_for_healthcare_professional":false,"catchline":"Announcement","featured_content_is_featured":false,"display_featured_image":true,"display_featured_image_as_hero":false,"_ml_titleColor":"#000000","_ml_titleFont":"Roboto","_ml_titleFontSize":1.136,"_ml_titleFontWeight":"400","_ml_titleLineHeight":1.3,"_ml_metaColor":"#708090","_ml_metaFont":"Montserrat","_ml_metaFontSize":0.6785,"_ml_metaFontWeight":"400","_ml_metaLineHeight":0.92,"_ml_bodyColor":"#a9a9a9","_ml_bodyFont":"Open Sans","_ml_bodyFontSize":0.85,"_ml_bodyFontWeight":"400","_ml_bodyLineHeight":1.2,"_ml_wooPriceColor":"#666","_ml_wooPriceFont":"Open Sans","_ml_wooPriceFontSize":0.9,"_ml_wooPriceFontWeight":"400","_ml_wooPriceLineHeight":1.27,"_ml_headingColor":"#000","_ml_headingFont":"Merriweather","_ml_headingFontSize":2.02,"_ml_headingFontWeight":"700","_ml_headingLineHeight":1.47,"_mlglobal_userfontcolors":{"headingColorUser":[],"titleColorUser":[],"metaColorUser":[],"bodyColorUser":[],"wooPriceColorUser":[]},"_oasis_is_in_workflow":0,"_oasis_original":0,"_oasis_task_priority":"","premium_content_is_premium":"yes","premium_content_render_panel":true,"stand_first":"","stand_first_render_panel":true,"footnotes":""},"article_tag":[],"section":[27],"news-type":[1352],"news-theme":[],"location":[],"career-stage":[],"learning-theme":[],"condition-treatment":[],"career-development":[],"subject":[],"class_list":["post-340973","news","type-news","status-publish","hentry","section-news","news-type-announcements"],"citation":{"data":{"publication":"The Pharmaceutical Journal","issue":"PJ, November 2023, Vol 311, No 7979","location":"311(7979):","doi":"10.1211\/PJ.2024.1.340973"},"rendered":"<i>The Pharmaceutical Journal<\/i>, PJ, November 2023, Vol 311, No 7979;311(7979)::DOI:10.1211\/PJ.2024.1.340973"},"article_extra":{"featured_image":[],"standfirst":"","references":[],"authors":[],"corresponding_authors":[],"is_promotional":false,"is_supported":false,"is_sponsored":false,"badge":"","article_excerpt":"The Royal Pharmaceutical Society Assembly has announced membership fees for 2025. The annual membership subscriptions are detailed in the table below. …","content_partners":[],"modified_datetime":"13 December 2024 4:50 pm","quiz":[]},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Royal Pharmaceutical Society membership fees 2025 - The Pharmaceutical Journal<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Royal Pharmaceutical Society membership fees 2025\" \/>\n<meta property=\"og:description\" content=\"The Royal Pharmaceutical Society Assembly has announced membership fees for 2025. The annual membership subscriptions are detailed in the table below. \" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025\" \/>\n<meta property=\"og:site_name\" content=\"The Pharmaceutical Journal\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/PharmaceuticalJournal\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-13T16:50:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/public.flourish.studio\/visualisation\/20779964\/thumbnail\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@PJOnline_News\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025\",\"url\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025\",\"name\":\"Royal Pharmaceutical Society membership fees 2025 - The Pharmaceutical Journal\",\"isPartOf\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025#primaryimage\"},\"thumbnailUrl\":\"https:\/\/public.flourish.studio\/visualisation\/20779964\/thumbnail\",\"datePublished\":\"2024-12-13T16:50:18+00:00\",\"dateModified\":\"2024-12-13T16:50:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025#primaryimage\",\"url\":\"https:\/\/public.flourish.studio\/visualisation\/20779964\/thumbnail\",\"contentUrl\":\"https:\/\/public.flourish.studio\/visualisation\/20779964\/thumbnail\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pharmaceutical-journal.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/pharmaceutical-journal.com\/article\/news\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Royal Pharmaceutical Society membership fees 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\",\"url\":\"https:\/\/pharmaceutical-journal.com\/\",\"name\":\"The Pharmaceutical Journal\",\"description\":\"The Pharmaceutical Journal from the Royal Pharmaceutical Society\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Royal Pharmaceutical Society membership fees 2025 - The Pharmaceutical Journal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025","og_locale":"en_US","og_type":"article","og_title":"Royal Pharmaceutical Society membership fees 2025","og_description":"The Royal Pharmaceutical Society Assembly has announced membership fees for 2025. The annual membership subscriptions are detailed in the table below. ","og_url":"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025","og_site_name":"The Pharmaceutical Journal","article_publisher":"https:\/\/www.facebook.com\/PharmaceuticalJournal","article_modified_time":"2024-12-13T16:50:20+00:00","og_image":[{"url":"https:\/\/public.flourish.studio\/visualisation\/20779964\/thumbnail"}],"twitter_card":"summary_large_image","twitter_site":"@PJOnline_News","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025","url":"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025","name":"Royal Pharmaceutical Society membership fees 2025 - The Pharmaceutical Journal","isPartOf":{"@id":"https:\/\/pharmaceutical-journal.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025#primaryimage"},"image":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025#primaryimage"},"thumbnailUrl":"https:\/\/public.flourish.studio\/visualisation\/20779964\/thumbnail","datePublished":"2024-12-13T16:50:18+00:00","dateModified":"2024-12-13T16:50:20+00:00","breadcrumb":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025#primaryimage","url":"https:\/\/public.flourish.studio\/visualisation\/20779964\/thumbnail","contentUrl":"https:\/\/public.flourish.studio\/visualisation\/20779964\/thumbnail"},{"@type":"BreadcrumbList","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/royal-pharmaceutical-society-membership-fees-2025#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pharmaceutical-journal.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/pharmaceutical-journal.com\/article\/news"},{"@type":"ListItem","position":3,"name":"Royal Pharmaceutical Society membership fees 2025"}]},{"@type":"WebSite","@id":"https:\/\/pharmaceutical-journal.com\/#website","url":"https:\/\/pharmaceutical-journal.com\/","name":"The Pharmaceutical Journal","description":"The Pharmaceutical Journal from the Royal Pharmaceutical Society","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340973"}],"collection":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/types\/news"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/comments?post=340973"}],"version-history":[{"count":4,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340973\/revisions"}],"predecessor-version":[{"id":341020,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340973\/revisions\/341020"}],"wp:attachment":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media?parent=340973"}],"wp:term":[{"taxonomy":"article_tag","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/article_tag?post=340973"},{"taxonomy":"section","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/section?post=340973"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-type?post=340973"},{"taxonomy":"news-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-theme?post=340973"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/location?post=340973"},{"taxonomy":"career-stage","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-stage?post=340973"},{"taxonomy":"learning-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/learning-theme?post=340973"},{"taxonomy":"condition-treatment","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/condition-treatment?post=340973"},{"taxonomy":"career-development","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-development?post=340973"},{"taxonomy":"subject","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/subject?post=340973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":340852,"date":"2024-12-13T15:38:05","date_gmt":"2024-12-13T15:38:05","guid":{"rendered":"https:\/\/pharmaceutical-journal.com\/?post_type=news&p=340852"},"modified":"2024-12-13T15:38:08","modified_gmt":"2024-12-13T15:38:08","slug":"government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff","status":"publish","type":"news","link":"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff","title":{"rendered":"Government plans for 2.8% pay uplift for hospital pharmacy staff"},"content":{"rendered":"<p>NHS Agenda for Change staff, including hospital pharmacists, should receive a 2.8% pay uplift for 2025\/2026, the Department of Health and Social Care (DHSC) has said.<\/p><p>In <a href=\"https:\/\/www.gov.uk\/government\/publications\/dhsc-evidence-for-the-nhsprb-pay-round-2025-to-2026?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=41821878-09a8-451b-aa24-2bde571cdeb7&utm_content=immediately\" target=\"_blank\" rel=\"noreferrer noopener\">written evidence to the NHS Pay Review Body<\/a>, published on 10 December 2024, the government said: \u201cDHSC has set aside a total of 2.8% to invest in pay for the Agenda for Change workforce in 2025 to 2026.”<\/p><p>It added that it views this \u201cas a reasonable amount to have set aside based on the macroeconomic data and forecasts and taking into account the fiscal and labour market context\u201d.<\/p><p>NHS England <a href=\"https:\/\/www.england.nhs.uk\/long-read\/submission-to-the-nhs-pay-review-body-evidence-for-the-2025-26-pay-round\/\" target=\"_blank\" rel=\"noreferrer noopener\">also recommended a 2.8% pay uplift in its submission to the NHS Pay Review Body<\/a>, saying that it had based its view on the \u201clikely NHS budget from discussions to date with DHSC\u201d and the 2024 autumn budget.<\/p><p>\u201cBased on this, we propose to set allocations for NHS planning on the basis of a 2.8% pay settlement. Every 0.5% increase above that costs around \u00a3700m; which is the equivalent to around 2% of elective activity (greater than 300k completed patient pathways),\u201d it added.<\/p><p>In July 2024, the government offered a 5.5% pay uplift to NHS staff in England for 2024\/2025, in line with a recommendation by the <a href=\"https:\/\/www.gov.uk\/government\/publications\/nhs-pay-review-body-thirty-seventh-report-2024\" target=\"_blank\" rel=\"noreferrer noopener\">NHS Pay Review Body<\/a>.<\/p><p>Unite the Union \u2014 which represents NHS staff and includes members of the Guild of Healthcare Pharmacists (GHP) \u2014 <a href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/hospital-pharmacists-vote-to-accept-5-5-pay-offer-from-uk-government\">announced in September 2024 that members had voted to accept the offer<\/a>, saying that \u201ctwo-thirds of Unite members working [for the NHS in England] have voted to say that they approve the government\u2019s decision to offer a 5.5% pay increase for 2024\/2025\u2033.<\/p><p>Sharon Graham, general secretary at Unite, described the recommended pay uplift for 2025\/2026 as an \u201cinsult\u201d.<\/p><p>\u201cThe NHS recruitment and retention crisis will not be solved without taking the issue of restorative pay seriously. The NHS still desperately needs to attract more workers after 14 years of below-inflation pay increases,\u201d she said.<\/p><p>\u201cThis latest below-inflation pay recommendation is an insult to dedicated NHS staff and further evidence that the [NHS] Pay Review Body is broken beyond repair.\u201d<\/p><p>\u201cUnite has long been saying that NHS pay concerns must be resolved through direct negotiations with government,\u201d Graham added.<\/p><p>Rob Connah, president of the GHP, said: “The proposed pay recommendation of 2.8% does not address restorative pay for staff on Agenda for Change.<\/p><p>“Real-terms pay has been decimated for over ten years. People should consider recent increases in their outgoings, such as mortgages, rent, utilities and food bills in addition to inflation, and how 2.8% would compare to those.” <\/p><p>NHS Agenda for Change staff in Scotland, Wales and Northern Ireland also a <a href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/hospital-pharmacists-to-receive-5-5-pay-rise\">received a 5.5% pay increase for 2024\/2025<\/a>, after accepting the UK government\u2019s offer in July 2024.<\/p><p>Unite announced in September 2024 that 93% of its members had voted to accept the NHS Scotland pay offer.<\/p><figure class=\"wp-block-embed is-type-rich is-provider-spotify wp-block-embed-spotify\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Spotify Embed: Spotlight: Safety of time-critical medicines\" style=\"border-radius: 12px\" width=\"100%\" height=\"152\" frameborder=\"0\" allowfullscreen allow=\"autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture\" loading=\"lazy\" src=\"https:\/\/open.spotify.com\/embed\/episode\/1yaebHLknS3mXDHFt4Xyci?si=dd6c62443d224a8a&utm_source=oembed\"><\/iframe>\n<\/div><\/figure>","protected":false},"excerpt":{"rendered":"<p>NHS Agenda for Change staff, including hospital pharmacists, should receive a 2.8% pay uplift for 2025\/2026, the Department of Health and Social Care (DHSC) has said. In written evidence to the NHS Pay Review Body, published on 10 December 2024, the government said: \u201cDHSC has set aside a total of 2.8% to invest in pay […]<\/p>\n","protected":false},"featured_media":340982,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"content_for_healthcare_professional":false,"catchline":"Employment terms and conditions","featured_content_is_featured":false,"display_featured_image":true,"display_featured_image_as_hero":false,"_ml_titleColor":"#000000","_ml_titleFont":"Roboto","_ml_titleFontSize":1.136,"_ml_titleFontWeight":"400","_ml_titleLineHeight":1.3,"_ml_metaColor":"#708090","_ml_metaFont":"Montserrat","_ml_metaFontSize":0.6785,"_ml_metaFontWeight":"400","_ml_metaLineHeight":0.92,"_ml_bodyColor":"#a9a9a9","_ml_bodyFont":"Open Sans","_ml_bodyFontSize":0.85,"_ml_bodyFontWeight":"400","_ml_bodyLineHeight":1.2,"_ml_wooPriceColor":"#666","_ml_wooPriceFont":"Open Sans","_ml_wooPriceFontSize":0.9,"_ml_wooPriceFontWeight":"400","_ml_wooPriceLineHeight":1.27,"_ml_headingColor":"#000","_ml_headingFont":"Merriweather","_ml_headingFontSize":2.02,"_ml_headingFontWeight":"700","_ml_headingLineHeight":1.47,"_mlglobal_userfontcolors":{"headingColorUser":[],"titleColorUser":[],"metaColorUser":[],"bodyColorUser":[],"wooPriceColorUser":[]},"_oasis_is_in_workflow":0,"_oasis_original":0,"_oasis_task_priority":"2normal","premium_content_is_premium":"yes","premium_content_render_panel":true,"stand_first":"Unite the Union described the pay increase an \u201cinsult\u201d, saying the NHS will not remedy its recruitment and retention crisis without tackling the issue of restorative pay. ","stand_first_render_panel":true,"footnotes":""},"article_tag":[],"section":[27],"news-type":[69],"news-theme":[78,88],"location":[31,33],"career-stage":[],"learning-theme":[],"condition-treatment":[],"career-development":[],"subject":[213,228,439,686,440,165,150,166,459,271,272,651,742,527,666,305,741,699,1372],"class_list":["post-340852","news","type-news","status-publish","has-post-thumbnail","hentry","section-news","news-type-latest-news","news-theme-hospital","news-theme-policy-and-politics","location-england","location-wales","subject-department-of-health-england","subject-employment","subject-employment-terms-and-conditions","subject-england","subject-england-nhs-structures","subject-government","subject-governmentorganization","subject-healthcare-provision","subject-hospital-pharmacy","subject-nhs","subject-nhs-commissioning-and-funding","subject-nhs-england","subject-pay","subject-pharmacy","subject-pharmacy-technician","subject-professions","subject-salary","subject-wales","subject-workforce"],"citation":{"data":{"publication":"The Pharmaceutical Journal","issue":"PJ, December 2024, Vol 313, No 7992","location":"313(7992):","doi":"10.1211\/PJ.2024.1.340852"},"rendered":"<i>The Pharmaceutical Journal<\/i>, PJ, December 2024, Vol 313, No 7992;313(7992)::DOI:10.1211\/PJ.2024.1.340852"},"article_extra":{"featured_image":{"src":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1952232043-927x617.jpg","sizes":{"small":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1952232043-469x312.jpg 469w","medium":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1952232043-650x433.jpg 650w","large":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1952232043-927x617.jpg 927w","xlarge":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1952232043-728x485.jpg 728w","retina":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1952232043-1456x967.jpg 1456w"},"alt_text":"Customer browses medicines in a pharmacy","caption":"NHS England has also recommended a 2.8% pay increase in its submission to the NHS Pay Review Body","source_credit":"Shutterstock.com"},"standfirst":"Unite the Union described the pay increase an \u201cinsult\u201d, saying the NHS will not remedy its recruitment and retention crisis without tackling the issue of restorative pay. ","references":[],"authors":[{"name":"Sophie Willis","image":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2021\/01\/2430-40x40.jpg","link":"https:\/\/pharmaceutical-journal.com\/author\/sophie-willis"}],"corresponding_authors":[],"is_promotional":false,"is_supported":false,"is_sponsored":false,"badge":"","article_excerpt":"Unite the Union described the pay increase an \u201cinsult\u201d, saying the NHS will not remedy its recruitment and retention crisis without tackling the issue of restorative pay.…","content_partners":[],"modified_datetime":"13 December 2024 3:38 pm","quiz":[]},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Government plans for 2.8% pay uplift for hospital pharmacy staff - The Pharmaceutical Journal<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Government plans for 2.8% pay uplift for hospital pharmacy staff\" \/>\n<meta property=\"og:description\" content=\"NHS Agenda for Change staff, including hospital pharmacists, should receive a 2.8% pay uplift for 2025\/2026, the Department of Health and Social Care (DHSC) has said. In written evidence to the NHS Pay Review Body, published on 10 December 2024, the government said: \u201cDHSC has set aside a total of 2.8% to invest in pay […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff\" \/>\n<meta property=\"og:site_name\" content=\"The Pharmaceutical Journal\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/PharmaceuticalJournal\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-13T15:38:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1952232043-scaled-e1734104082923.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@PJOnline_News\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff\",\"url\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff\",\"name\":\"Government plans for 2.8% pay uplift for hospital pharmacy staff - The Pharmaceutical Journal\",\"isPartOf\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1952232043-scaled-e1734104082923.jpg\",\"datePublished\":\"2024-12-13T15:38:05+00:00\",\"dateModified\":\"2024-12-13T15:38:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff#primaryimage\",\"url\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1952232043-scaled-e1734104082923.jpg\",\"contentUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1952232043-scaled-e1734104082923.jpg\",\"width\":1024,\"height\":576,\"caption\":\"NHS England has also recommended a 2.8% pay increase in its submission to the NHS Pay Review Body\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pharmaceutical-journal.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/pharmaceutical-journal.com\/article\/news\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Government plans for 2.8% pay uplift for hospital pharmacy staff\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\",\"url\":\"https:\/\/pharmaceutical-journal.com\/\",\"name\":\"The Pharmaceutical Journal\",\"description\":\"The Pharmaceutical Journal from the Royal Pharmaceutical Society\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Government plans for 2.8% pay uplift for hospital pharmacy staff - The Pharmaceutical Journal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff","og_locale":"en_US","og_type":"article","og_title":"Government plans for 2.8% pay uplift for hospital pharmacy staff","og_description":"NHS Agenda for Change staff, including hospital pharmacists, should receive a 2.8% pay uplift for 2025\/2026, the Department of Health and Social Care (DHSC) has said. In written evidence to the NHS Pay Review Body, published on 10 December 2024, the government said: \u201cDHSC has set aside a total of 2.8% to invest in pay […]","og_url":"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff","og_site_name":"The Pharmaceutical Journal","article_publisher":"https:\/\/www.facebook.com\/PharmaceuticalJournal","article_modified_time":"2024-12-13T15:38:08+00:00","og_image":[{"width":1024,"height":576,"url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1952232043-scaled-e1734104082923.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@PJOnline_News","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff","url":"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff","name":"Government plans for 2.8% pay uplift for hospital pharmacy staff - The Pharmaceutical Journal","isPartOf":{"@id":"https:\/\/pharmaceutical-journal.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff#primaryimage"},"image":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff#primaryimage"},"thumbnailUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1952232043-scaled-e1734104082923.jpg","datePublished":"2024-12-13T15:38:05+00:00","dateModified":"2024-12-13T15:38:08+00:00","breadcrumb":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff#primaryimage","url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1952232043-scaled-e1734104082923.jpg","contentUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1952232043-scaled-e1734104082923.jpg","width":1024,"height":576,"caption":"NHS England has also recommended a 2.8% pay increase in its submission to the NHS Pay Review Body"},{"@type":"BreadcrumbList","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/government-plans-for-2-8-pay-uplift-for-hospital-pharmacy-staff#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pharmaceutical-journal.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/pharmaceutical-journal.com\/article\/news"},{"@type":"ListItem","position":3,"name":"Government plans for 2.8% pay uplift for hospital pharmacy staff"}]},{"@type":"WebSite","@id":"https:\/\/pharmaceutical-journal.com\/#website","url":"https:\/\/pharmaceutical-journal.com\/","name":"The Pharmaceutical Journal","description":"The Pharmaceutical Journal from the Royal Pharmaceutical Society","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340852"}],"collection":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/types\/news"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/comments?post=340852"}],"version-history":[{"count":4,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340852\/revisions"}],"predecessor-version":[{"id":341011,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340852\/revisions\/341011"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media\/340982"}],"wp:attachment":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media?parent=340852"}],"wp:term":[{"taxonomy":"article_tag","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/article_tag?post=340852"},{"taxonomy":"section","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/section?post=340852"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-type?post=340852"},{"taxonomy":"news-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-theme?post=340852"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/location?post=340852"},{"taxonomy":"career-stage","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-stage?post=340852"},{"taxonomy":"learning-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/learning-theme?post=340852"},{"taxonomy":"condition-treatment","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/condition-treatment?post=340852"},{"taxonomy":"career-development","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-development?post=340852"},{"taxonomy":"subject","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/subject?post=340852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":340596,"date":"2024-12-13T12:49:51","date_gmt":"2024-12-13T12:49:51","guid":{"rendered":"https:\/\/pharmaceutical-journal.com\/?post_type=news&p=340596"},"modified":"2024-12-13T12:49:53","modified_gmt":"2024-12-13T12:49:53","slug":"nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy","status":"publish","type":"news","link":"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy","title":{"rendered":"NICE recommends alternative corticosteroid for people with Duchenne muscular dystrophy"},"content":{"rendered":"<p>Vamorolone (Agamree; Santhera), a corticosteroid, has been recommended for the treatment of Duchenne muscular dystrophy (DMD) in people aged four years and over by the National Institute for Health and Care Excellence (NICE).<\/p><p>In <a href=\"https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11135\" target=\"_blank\" rel=\"noreferrer noopener\">final draft guidance published on 10 December 2024<\/a>, NICE recommended the treatment as an alternative to other available corticosteroids used to reduce muscle inflammation and maintain muscle strength and function in people with DMD.<\/p><p><a href=\"https:\/\/www.nice.org.uk\/news\/articles\/new-price-deal-paves-way-for-nice-approval-of-treatment-for-rare-genetic-condition\" target=\"_blank\" rel=\"noreferrer noopener\">NICE said that the treatment would be available to around 1,700 people in England<\/a> and it could offer \u201cimportant benefits because of its potential to reduce adverse events\u201d associated with currently available corticosteroids, which can include osteoporosis, weight gain and delayed puberty.<\/p><p>DMD is an incurable genetic condition that causes progressive muscle loss. It primarily affects boys and is usually diagnosed between the ages of three years and six years. Patients with the condition have decreased life expectancy, mostly living into their 20s and 30s.<\/p><p>Other corticosteroids used in the treatment of the condition include prednisone, prednisolone and deflazacort.<\/p><p>NICE previously concluded that more evidence was needed to establish the cost-effectiveness of vamorolone. However, in the final draft guidance, NICE said that new analysis presented by the manufacturer, along with an improved discount to the price of the treatment, meant that it could recommend it as a \u201ccost-effective use of NHS resources\u201d.<\/p><p>Commenting on the guidance, Rob Burley, director of care, campaigns and support at the charity Muscular Dystrophy UK, said<strong>:<\/strong> “It\u2019s great news that NICE has recommended vamorolone for people aged four [years] and over with DMD in England, giving individuals and families an alternative treatment option.\u00a0<\/p><p>\u201cWe\u2019re proud to have played a key role in the appraisal process, including nominating and supporting a patient expert to share her son’s experience of receiving the treatment through a clinical trial. Throughout the appraisal process, we heard first-hand about the dilemma that families face when it is recommended that their child starts taking corticosteroids due to the associated side effects, and the benefits an alternative choice would bring.”<\/p><p>Helen Knight, director of medicines evaluation at NICE, said<strong>: <\/strong>\u201cThe committee felt vamorolone could offer important benefits to patients and their families because of its potential to reduce adverse events associated with current steroid treatments. <\/p><p>\u201cGiven the significant burden this disease places on children with the condition and on their parents and carers, as well as the negative impact this can have on their quality of life, a treatment with the potential to reduce side effects associated with current treatments is to be welcomed.\u201d <\/p><p>\u201cWe\u2019re therefore delighted the company has been able to work with us to enable vamorolone to be made available to people with DMD,\u201d she added.\u00a0\u00a0\u00a0<\/p><p>In its statement, NICE said vamorolone is \u201cone of several non-cancer treatments recommended by NICE following the introduction of the new severity modifier\u201d.<\/p><p>\u201cThis allows NICE\u2019s independent committees to give greater weight to severe conditions, including conditions such as DMD, that would not have qualified for additional weighting under the previous end of life criteria,\u201d it added.<\/p><p>NICE introduced the severity modifier in February 2022, replacing the previous \u2018end-of-life modifier\u2019, to provide an additional weighting to the \u2018value\u2019 of some medicines that treat more severe conditions.<\/p><p>In November 2024, a <a href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-may-be-systematically-undervaluing-medicines-for-severe-conditions-says-abpi\">report by the Office of Health Economics<\/a> said the severity modifier may be blocking innovative treatments that the public would like to see benefit NHS patients.<\/p><figure class=\"wp-block-embed is-type-rich is-provider-spotify wp-block-embed-spotify\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Spotify Embed: Spotlight: Safety of time-critical medicines\" style=\"border-radius: 12px\" width=\"100%\" height=\"152\" frameborder=\"0\" allowfullscreen allow=\"autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture\" loading=\"lazy\" src=\"https:\/\/open.spotify.com\/embed\/episode\/1yaebHLknS3mXDHFt4Xyci?si=a1WGid2kTGW-0Bt5i4zz_w&utm_source=oembed\"><\/iframe>\n<\/div><\/figure>","protected":false},"excerpt":{"rendered":"<p>Vamorolone (Agamree; Santhera), a corticosteroid, has been recommended for the treatment of Duchenne muscular dystrophy (DMD) in people aged four years and over by the National Institute for Health and Care Excellence (NICE). In final draft guidance published on 10 December 2024, NICE recommended the treatment as an alternative to other available corticosteroids used to […]<\/p>\n","protected":false},"featured_media":340875,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"content_for_healthcare_professional":false,"catchline":"Muscular dystrophy","featured_content_is_featured":false,"display_featured_image":true,"display_featured_image_as_hero":false,"_ml_titleColor":"#000000","_ml_titleFont":"Roboto","_ml_titleFontSize":1.136,"_ml_titleFontWeight":"400","_ml_titleLineHeight":1.3,"_ml_metaColor":"#708090","_ml_metaFont":"Montserrat","_ml_metaFontSize":0.6785,"_ml_metaFontWeight":"400","_ml_metaLineHeight":0.92,"_ml_bodyColor":"#a9a9a9","_ml_bodyFont":"Open Sans","_ml_bodyFontSize":0.85,"_ml_bodyFontWeight":"400","_ml_bodyLineHeight":1.2,"_ml_wooPriceColor":"#666","_ml_wooPriceFont":"Open Sans","_ml_wooPriceFontSize":0.9,"_ml_wooPriceFontWeight":"400","_ml_wooPriceLineHeight":1.27,"_ml_headingColor":"#000","_ml_headingFont":"Merriweather","_ml_headingFontSize":2.02,"_ml_headingFontWeight":"700","_ml_headingLineHeight":1.47,"_mlglobal_userfontcolors":{"headingColorUser":[],"titleColorUser":[],"metaColorUser":[],"bodyColorUser":[],"wooPriceColorUser":[]},"_oasis_is_in_workflow":0,"_oasis_original":0,"_oasis_task_priority":"2normal","premium_content_is_premium":"yes","premium_content_render_panel":true,"stand_first":"The guidance says that vamorolone reduces \u201cadverse events\u201d that are tied to other currently available corticosteroids, which include osteoporosis, weight gain and delayed puberty.","stand_first_render_panel":true,"footnotes":""},"article_tag":[],"section":[27],"news-type":[69],"news-theme":[],"location":[],"career-stage":[],"learning-theme":[],"condition-treatment":[51,1331],"career-development":[],"subject":[209,264,173,174],"class_list":["post-340596","news","type-news","status-publish","has-post-thumbnail","hentry","section-news","news-type-latest-news","condition-treatment-genetic-disorders","condition-treatment-genetics","subject-congenital-hereditary-and-neonatal-diseases-and-abnormalities","subject-medicines-regulation-and-law","subject-pharmaceutical-companies","subject-pharmaceutical-industry"],"citation":{"data":{"publication":"The Pharmaceutical Journal","issue":"PJ, December 2024, Vol 313, No 7992","location":"313(7992):","doi":"10.1211\/PJ.2024.1.340596"},"rendered":"<i>The Pharmaceutical Journal<\/i>, PJ, December 2024, Vol 313, No 7992;313(7992)::DOI:10.1211\/PJ.2024.1.340596"},"article_extra":{"featured_image":{"src":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1894082203-927x617.jpg","sizes":{"small":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1894082203-469x312.jpg 469w","medium":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1894082203-650x433.jpg 650w","large":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1894082203-927x617.jpg 927w","xlarge":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1894082203-728x485.jpg 728w","retina":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1894082203-1456x967.jpg 1456w"},"alt_text":"Doctor consults child with muscular dystrophy","caption":"The National Institute for Health and Care Excellence said vamorolone treatment would be available to around 1,700 people in England ","source_credit":"Shutterstock.com"},"standfirst":"The guidance says that vamorolone reduces \u201cadverse events\u201d that are tied to other currently available corticosteroids, which include osteoporosis, weight gain and delayed puberty.","references":[],"authors":[{"name":"Sophie Willis","image":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2021\/01\/2430-40x40.jpg","link":"https:\/\/pharmaceutical-journal.com\/author\/sophie-willis"}],"corresponding_authors":[],"is_promotional":false,"is_supported":false,"is_sponsored":false,"badge":"","article_excerpt":"The guidance says that vamorolone reduces \u201cadverse events\u201d that are tied to other currently available corticosteroids, which include osteoporosis, weight gain and delayed puberty.…","content_partners":[],"modified_datetime":"13 December 2024 12:49 pm","quiz":[]},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NICE recommends alternative corticosteroid for people with Duchenne muscular dystrophy - The Pharmaceutical Journal<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NICE recommends alternative corticosteroid for people with Duchenne muscular dystrophy\" \/>\n<meta property=\"og:description\" content=\"Vamorolone (Agamree; Santhera), a corticosteroid, has been recommended for the treatment of Duchenne muscular dystrophy (DMD) in people aged four years and over by the National Institute for Health and Care Excellence (NICE). In final draft guidance published on 10 December 2024, NICE recommended the treatment as an alternative to other available corticosteroids used to […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy\" \/>\n<meta property=\"og:site_name\" content=\"The Pharmaceutical Journal\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/PharmaceuticalJournal\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-13T12:49:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1894082203-scaled-e1734093718640.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"520\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@PJOnline_News\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy\",\"url\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy\",\"name\":\"NICE recommends alternative corticosteroid for people with Duchenne muscular dystrophy - The Pharmaceutical Journal\",\"isPartOf\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1894082203-scaled-e1734093718640.jpg\",\"datePublished\":\"2024-12-13T12:49:51+00:00\",\"dateModified\":\"2024-12-13T12:49:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy#primaryimage\",\"url\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1894082203-scaled-e1734093718640.jpg\",\"contentUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1894082203-scaled-e1734093718640.jpg\",\"width\":1024,\"height\":520,\"caption\":\"The National Institute for Health and Care Excellence said vamorolone treatment would be available to around 1,700 people in England\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pharmaceutical-journal.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/pharmaceutical-journal.com\/article\/news\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"NICE recommends alternative corticosteroid for people with Duchenne muscular dystrophy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\",\"url\":\"https:\/\/pharmaceutical-journal.com\/\",\"name\":\"The Pharmaceutical Journal\",\"description\":\"The Pharmaceutical Journal from the Royal Pharmaceutical Society\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NICE recommends alternative corticosteroid for people with Duchenne muscular dystrophy - The Pharmaceutical Journal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy","og_locale":"en_US","og_type":"article","og_title":"NICE recommends alternative corticosteroid for people with Duchenne muscular dystrophy","og_description":"Vamorolone (Agamree; Santhera), a corticosteroid, has been recommended for the treatment of Duchenne muscular dystrophy (DMD) in people aged four years and over by the National Institute for Health and Care Excellence (NICE). In final draft guidance published on 10 December 2024, NICE recommended the treatment as an alternative to other available corticosteroids used to […]","og_url":"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy","og_site_name":"The Pharmaceutical Journal","article_publisher":"https:\/\/www.facebook.com\/PharmaceuticalJournal","article_modified_time":"2024-12-13T12:49:53+00:00","og_image":[{"width":1024,"height":520,"url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1894082203-scaled-e1734093718640.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@PJOnline_News","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy","url":"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy","name":"NICE recommends alternative corticosteroid for people with Duchenne muscular dystrophy - The Pharmaceutical Journal","isPartOf":{"@id":"https:\/\/pharmaceutical-journal.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy#primaryimage"},"image":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy#primaryimage"},"thumbnailUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1894082203-scaled-e1734093718640.jpg","datePublished":"2024-12-13T12:49:51+00:00","dateModified":"2024-12-13T12:49:53+00:00","breadcrumb":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy#primaryimage","url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1894082203-scaled-e1734093718640.jpg","contentUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1894082203-scaled-e1734093718640.jpg","width":1024,"height":520,"caption":"The National Institute for Health and Care Excellence said vamorolone treatment would be available to around 1,700 people in England"},{"@type":"BreadcrumbList","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-alternative-corticosteroid-for-people-with-duchenne-muscular-dystrophy#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pharmaceutical-journal.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/pharmaceutical-journal.com\/article\/news"},{"@type":"ListItem","position":3,"name":"NICE recommends alternative corticosteroid for people with Duchenne muscular dystrophy"}]},{"@type":"WebSite","@id":"https:\/\/pharmaceutical-journal.com\/#website","url":"https:\/\/pharmaceutical-journal.com\/","name":"The Pharmaceutical Journal","description":"The Pharmaceutical Journal from the Royal Pharmaceutical Society","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340596"}],"collection":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/types\/news"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/comments?post=340596"}],"version-history":[{"count":4,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340596\/revisions"}],"predecessor-version":[{"id":340972,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340596\/revisions\/340972"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media\/340875"}],"wp:attachment":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media?parent=340596"}],"wp:term":[{"taxonomy":"article_tag","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/article_tag?post=340596"},{"taxonomy":"section","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/section?post=340596"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-type?post=340596"},{"taxonomy":"news-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-theme?post=340596"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/location?post=340596"},{"taxonomy":"career-stage","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-stage?post=340596"},{"taxonomy":"learning-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/learning-theme?post=340596"},{"taxonomy":"condition-treatment","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/condition-treatment?post=340596"},{"taxonomy":"career-development","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-development?post=340596"},{"taxonomy":"subject","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/subject?post=340596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":340645,"date":"2024-12-13T12:40:56","date_gmt":"2024-12-13T12:40:56","guid":{"rendered":"https:\/\/pharmaceutical-journal.com\/?post_type=news&p=340645"},"modified":"2024-12-13T12:40:58","modified_gmt":"2024-12-13T12:40:58","slug":"manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment","status":"publish","type":"news","link":"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment","title":{"rendered":"Manufacturer offers NHS \u00a323m in response to investigation into misleading claims about rival treatment"},"content":{"rendered":"<p>Drugs manufacturer Vifor Pharma has offered to pay \u00a323m to the NHS in response to an investigation by the Competition and Markets Authority (CMA) into whether the company had broken competition law by spreading misinformation about a rival product.<\/p><p>The CMA opened an investigation in January 2024 into whether Vifor Pharma, which manufactures the IV iron deficiency treatment Ferinject, had restricted competition by spreading misinformation to healthcare professionals about the safety of a rival treatment, Monofer, which is manufactured by Pharmacosmos. <\/p><p>In a <a href=\"https:\/\/www.gov.uk\/government\/news\/nhs-set-to-benefit-from-23-million-following-cma-pharma-probe\" target=\"_blank\" rel=\"noreferrer noopener\">statement published on 10 December 2024<\/a>, the CMA confirmed that Vifor Pharma had offered several commitments, which the CMA will consult on.<\/p><p>These include making a payment of \u00a323m to healthcare systems across the UK\u2019s four nations, \u201cfollowing concerns that the claims could have an adverse financial impact on the NHS\u201d.<\/p><p>It has also agreed to write to healthcare professionals to \u201ccorrect any potentially misleading communications regarding the safety of Monofer and Ferinject\u201d and introduce measures to prevent dissemination of misleading information in the future, the CMA statement said.<\/p><p>\u201cIf accepted, the commitments will become legally binding and will mean that it is not necessary for the CMA to decide whether Vifor Pharma broke competition law \u2014 allowing the investigation to conclude swiftly, so that the benefits can be felt sooner,\u201d it added.<\/p><p>Juliette Enser, executive director for competition enforcement at the CMA, said: \u201cPharmaceutical companies must think carefully when making claims about competitors \u2014 these can have real impact on the doctors and nurses making potentially life-changing decisions about treatment and, of course, on the patients themselves. <\/p><p>\u201cAs well as ensuring patients are protected, the commitments we are consulting on support competition \u2014 enabling businesses to operate on an even playing field and the NHS to get good value for money.\u201d<\/p><p>In its statement, the CMA said that this was the \u201cfirst time a misleading claims case of this nature has been investigated by the CMA under its competition law enforcement powers\u201d.<\/p><p>Vifor Pharma was investigated by the European Commission over the same misinformation claims.<\/p><p>The commission <a href=\"https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/ip_22_3882\" target=\"_blank\" rel=\"noreferrer noopener\">opened its investigation in June 2022<\/a> \u201cto assess whether Vifor Pharma has restricted competition by illegally disparaging its closest \u2014 and potentially only \u2014 competitor in Europe on the market for intravenous iron treatment\u201d.<\/p><p>It concluded the investigation in July 2024, <a href=\"https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/ip_24_3907\" target=\"_blank\" rel=\"noreferrer noopener\">after accepting commitments from the company, which it made legally binding<\/a>.<\/p><p>The commitments included that Vifor would \u201claunch a comprehensive and multi-channel communication campaign to rectify and undo the effects of the potentially misleading messages previously disseminated by Vifor regarding the safety of Monofer\u201d and \u201cimplement measures and safeguards to ensure compliance\u201d.<\/p><p>In a statement given to <em>The Pharmaceutical Journal<\/em>, a spokesperson for Vifor Pharma said: \u201cCSL Vifor acknowledges that the UK\u2019s CMA has initiated a public consultation as part of the CMA\u2019s investigation into potential anti-competitive conduct of Vifor Pharma, and published CSL Vifor\u2019s proposed commitments on their website.<\/p><p>\u201cIt is important to note that the commitments were offered without any admission of liability. CSL Vifor is pleased to be taking this important step towards resolution of the CMA investigation. As this is an ongoing investigation, we are not in a position to comment further at this time.\u201d<\/p><p>The <a href=\"https:\/\/www.gov.uk\/government\/consultations\/consultation-on-proposed-commitments-in-respect-of-vifor-pharmas-supply-of-intravenous-iron\" target=\"_blank\" rel=\"noreferrer noopener\">CMA\u2019s consultation on Vifor\u2019s commitments<\/a> will close on 17 January 2025.<\/p><figure class=\"wp-block-embed is-type-rich is-provider-spotify wp-block-embed-spotify\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Spotify Embed: Spotlight: Safety of time-critical medicines\" style=\"border-radius: 12px\" width=\"100%\" height=\"152\" frameborder=\"0\" allowfullscreen allow=\"autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture\" loading=\"lazy\" src=\"https:\/\/open.spotify.com\/embed\/episode\/1yaebHLknS3mXDHFt4Xyci?utm_source=oembed\"><\/iframe>\n<\/div><\/figure>","protected":false},"excerpt":{"rendered":"<p>Drugs manufacturer Vifor Pharma has offered to pay \u00a323m to the NHS in response to an investigation by the Competition and Markets Authority (CMA) into whether the company had broken competition law by spreading misinformation about a rival product. The CMA opened an investigation in January 2024 into whether Vifor Pharma, which manufactures the IV […]<\/p>\n","protected":false},"featured_media":340764,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"content_for_healthcare_professional":false,"catchline":"Medicines regulation and law","featured_content_is_featured":false,"display_featured_image":true,"display_featured_image_as_hero":false,"_ml_titleColor":"#000000","_ml_titleFont":"Roboto","_ml_titleFontSize":1.136,"_ml_titleFontWeight":"400","_ml_titleLineHeight":1.3,"_ml_metaColor":"#708090","_ml_metaFont":"Montserrat","_ml_metaFontSize":0.6785,"_ml_metaFontWeight":"400","_ml_metaLineHeight":0.92,"_ml_bodyColor":"#a9a9a9","_ml_bodyFont":"Open Sans","_ml_bodyFontSize":0.85,"_ml_bodyFontWeight":"400","_ml_bodyLineHeight":1.2,"_ml_wooPriceColor":"#666","_ml_wooPriceFont":"Open Sans","_ml_wooPriceFontSize":0.9,"_ml_wooPriceFontWeight":"400","_ml_wooPriceLineHeight":1.27,"_ml_headingColor":"#000","_ml_headingFont":"Merriweather","_ml_headingFontSize":2.02,"_ml_headingFontWeight":"700","_ml_headingLineHeight":1.47,"_mlglobal_userfontcolors":{"headingColorUser":[],"titleColorUser":[],"metaColorUser":[],"bodyColorUser":[],"wooPriceColorUser":[]},"_oasis_is_in_workflow":0,"_oasis_original":0,"_oasis_task_priority":"2normal","premium_content_is_premium":"yes","premium_content_render_panel":true,"stand_first":"Vifor Pharma has also agreed to write to healthcare professionals to “correct any potentially misleading communications regarding the safety of Monofer and Ferinject”.","stand_first_render_panel":true,"footnotes":""},"article_tag":[],"section":[27],"news-type":[69],"news-theme":[80],"location":[],"career-stage":[],"learning-theme":[],"condition-treatment":[],"career-development":[],"subject":[426,166,264,272,174,292,728],"class_list":["post-340645","news","type-news","status-publish","has-post-thumbnail","hentry","section-news","news-type-latest-news","news-theme-industry","subject-drug-pricing","subject-healthcare-provision","subject-medicines-regulation-and-law","subject-nhs-commissioning-and-funding","subject-pharmaceutical-industry","subject-pharmaceutics","subject-uk-healthcare"],"citation":{"data":{"publication":"The Pharmaceutical Journal","issue":"PJ, December 2024, Vol 313, No 7992","location":"313(7992):","doi":"10.1211\/PJ.2024.1.340645"},"rendered":"<i>The Pharmaceutical Journal<\/i>, PJ, December 2024, Vol 313, No 7992;313(7992)::DOI:10.1211\/PJ.2024.1.340645"},"article_extra":{"featured_image":{"src":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/vifor-pharma-927x617.jpg","sizes":{"small":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/vifor-pharma-469x312.jpg 469w","medium":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/vifor-pharma-650x433.jpg 650w","large":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/vifor-pharma-927x617.jpg 927w","xlarge":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/vifor-pharma-728x485.jpg 728w","retina":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/vifor-pharma.jpg 1456w"},"alt_text":"Vifor Pharma logo on mobile phone screen","caption":"Vifor Pharma was investigated by the European Commission over the same misinformation claims","source_credit":"SOPA Images Limited \/ Alamy Stock Photo"},"standfirst":"Vifor Pharma has also agreed to write to healthcare professionals to “correct any potentially misleading communications regarding the safety of Monofer and Ferinject”.","references":[],"authors":[{"name":"Sophie Willis","image":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2021\/01\/2430-40x40.jpg","link":"https:\/\/pharmaceutical-journal.com\/author\/sophie-willis"}],"corresponding_authors":[],"is_promotional":false,"is_supported":false,"is_sponsored":false,"badge":"","article_excerpt":"Vifor Pharma has also agreed to write to healthcare professionals to “correct any potentially misleading communications regarding the safety of Monofer and Ferinject”.…","content_partners":[],"modified_datetime":"13 December 2024 12:40 pm","quiz":[]},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Manufacturer offers NHS \u00a323m in response to investigation into misleading claims about rival treatment - The Pharmaceutical Journal<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Manufacturer offers NHS \u00a323m in response to investigation into misleading claims about rival treatment\" \/>\n<meta property=\"og:description\" content=\"Drugs manufacturer Vifor Pharma has offered to pay \u00a323m to the NHS in response to an investigation by the Competition and Markets Authority (CMA) into whether the company had broken competition law by spreading misinformation about a rival product. The CMA opened an investigation in January 2024 into whether Vifor Pharma, which manufactures the IV […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment\" \/>\n<meta property=\"og:site_name\" content=\"The Pharmaceutical Journal\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/PharmaceuticalJournal\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-13T12:40:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/vifor-pharma.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"681\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@PJOnline_News\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment\",\"url\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment\",\"name\":\"Manufacturer offers NHS \u00a323m in response to investigation into misleading claims about rival treatment - The Pharmaceutical Journal\",\"isPartOf\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/vifor-pharma.jpg\",\"datePublished\":\"2024-12-13T12:40:56+00:00\",\"dateModified\":\"2024-12-13T12:40:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment#primaryimage\",\"url\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/vifor-pharma.jpg\",\"contentUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/vifor-pharma.jpg\",\"width\":1024,\"height\":681,\"caption\":\"Vifor Pharma was investigated by the European Commission over the same misinformation claims\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pharmaceutical-journal.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/pharmaceutical-journal.com\/article\/news\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Manufacturer offers NHS \u00a323m in response to investigation into misleading claims about rival treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\",\"url\":\"https:\/\/pharmaceutical-journal.com\/\",\"name\":\"The Pharmaceutical Journal\",\"description\":\"The Pharmaceutical Journal from the Royal Pharmaceutical Society\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Manufacturer offers NHS \u00a323m in response to investigation into misleading claims about rival treatment - The Pharmaceutical Journal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment","og_locale":"en_US","og_type":"article","og_title":"Manufacturer offers NHS \u00a323m in response to investigation into misleading claims about rival treatment","og_description":"Drugs manufacturer Vifor Pharma has offered to pay \u00a323m to the NHS in response to an investigation by the Competition and Markets Authority (CMA) into whether the company had broken competition law by spreading misinformation about a rival product. The CMA opened an investigation in January 2024 into whether Vifor Pharma, which manufactures the IV […]","og_url":"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment","og_site_name":"The Pharmaceutical Journal","article_publisher":"https:\/\/www.facebook.com\/PharmaceuticalJournal","article_modified_time":"2024-12-13T12:40:58+00:00","og_image":[{"width":1024,"height":681,"url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/vifor-pharma.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@PJOnline_News","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment","url":"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment","name":"Manufacturer offers NHS \u00a323m in response to investigation into misleading claims about rival treatment - The Pharmaceutical Journal","isPartOf":{"@id":"https:\/\/pharmaceutical-journal.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment#primaryimage"},"image":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment#primaryimage"},"thumbnailUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/vifor-pharma.jpg","datePublished":"2024-12-13T12:40:56+00:00","dateModified":"2024-12-13T12:40:58+00:00","breadcrumb":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment#primaryimage","url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/vifor-pharma.jpg","contentUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/vifor-pharma.jpg","width":1024,"height":681,"caption":"Vifor Pharma was investigated by the European Commission over the same misinformation claims"},{"@type":"BreadcrumbList","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/manufacturer-offers-nhs-23m-in-response-to-investigation-into-misleading-claims-about-rival-treatment#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pharmaceutical-journal.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/pharmaceutical-journal.com\/article\/news"},{"@type":"ListItem","position":3,"name":"Manufacturer offers NHS \u00a323m in response to investigation into misleading claims about rival treatment"}]},{"@type":"WebSite","@id":"https:\/\/pharmaceutical-journal.com\/#website","url":"https:\/\/pharmaceutical-journal.com\/","name":"The Pharmaceutical Journal","description":"The Pharmaceutical Journal from the Royal Pharmaceutical Society","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340645"}],"collection":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/types\/news"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/comments?post=340645"}],"version-history":[{"count":4,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340645\/revisions"}],"predecessor-version":[{"id":340969,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340645\/revisions\/340969"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media\/340764"}],"wp:attachment":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media?parent=340645"}],"wp:term":[{"taxonomy":"article_tag","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/article_tag?post=340645"},{"taxonomy":"section","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/section?post=340645"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-type?post=340645"},{"taxonomy":"news-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-theme?post=340645"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/location?post=340645"},{"taxonomy":"career-stage","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-stage?post=340645"},{"taxonomy":"learning-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/learning-theme?post=340645"},{"taxonomy":"condition-treatment","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/condition-treatment?post=340645"},{"taxonomy":"career-development","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-development?post=340645"},{"taxonomy":"subject","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/subject?post=340645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":340842,"date":"2024-12-12T15:07:58","date_gmt":"2024-12-12T15:07:58","guid":{"rendered":"https:\/\/pharmaceutical-journal.com\/?post_type=news&p=340842"},"modified":"2024-12-12T15:08:00","modified_gmt":"2024-12-12T15:08:00","slug":"first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system","status":"publish","type":"news","link":"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system","title":{"rendered":"First independent prescribing pathfinder pharmacy goes live using tailored IT system"},"content":{"rendered":"<p>Well Pharmacy in Keighley, West Yorkshire, has become the first community pharmacy to go live as part of the ‘Independent prescribing in community pharmacy pathfinder programme’, using an electronic prescription service (EPS) specifically designed for the pilot.<\/p><p>Under the pathfinder programme, 210 community pharmacies across all 42 integrated care boards (ICBs) in England will trial independent prescribing for a range of conditions, including minor illnesses and long-term conditions, as part of a locally-commissioned \u2014 but nationally funded \u2014 clinical service.<\/p><p>The pilot has been highly anticipated following the news that, from 2026, all newly qualified pharmacists would become prescribers from the point of registration.<\/p><p>IT provider CLEO Systems is hosting the EPS that will be used by pharmacies participating in the pilot, and it was <a href=\"\/article\/news\/it-system-for-independent-prescribing-pathfinder-programme-ready-for-rollout-says-nhs-england\">announced in August 2024 that the system was ready for rollout<\/a>.<\/p><p>Ifti Khan, pharmacy superintendent at Well Pharmacy, which is part of the Bestway Group, said: \u201cOur colleagues were excited to have the opportunity to support this transformational initiative and the wider NHS, enabling pharmacy to truly be the first point of contact for patients with minor ailments.\u201d<\/p><p>\u201cWe are looking forward to watching the benefit this service will have to local patients and how we can continue to support the government\u2019s agenda of Pharmacy First and early detection and prevention,\u201d he added.<\/p><p>While the Well Pharmacy branch in Keighley, West Yorkshire is the first ‘pathfinder site’ to use the CLEO EPS system, Wasim Baqir, senior pharmacist for the Pharmacy Integration Fund at NHS England, announced at the Clinical Pharmacy Congress in May 2024, that <a href=\"\/article\/news\/first-14-independent-prescribing-pathfinder-sites-have-gone-live-says-nhs-england\">14 pathfinder sites had gone live prior to the EPS being ready<\/a>.<\/p><p>Commenting on the Keighley site, Richard Burton, commercial director at CLEO Systems, said: \u201cWe are so pleased to see the success of this first deployment of CLEO SOLO EPS in this ambitious and exciting project. It has been an absolute pleasure for the team to work with NHS England, the ICBs, other system providers and pharmacies on this significant programme.\u201d<\/p><p>A spokesperson for NHS England said: \u201cThe ‘Independent prescribing pathfinder programme’ is designed to help the health service prepare for the inclusion of prescribing in community pharmacy-based clinical services, which will improve patient access to care in a safe way. <\/p><p>“This is part of our plan for all newly qualified pharmacists to be trained in prescribing from 2026 onwards.\u201d<\/p><p>The <a href=\"https:\/\/pharmaceutical-journal.com\/article\/feature\/a-prescribing-service-for-englands-pharmacies-everything-you-need-to-know\">pathfinder programme<\/a> is aimed to explore how community pharmacists can deliver independent prescribing across all regions of England, ahead of <a href=\"\/article\/news\/nhs-could-introduce-performers-list-for-independent-prescribing-pharmacists\">establishing a national commissioning framework for the service, which was originally scheduled for March 2024<\/a>.<\/p><p>The pathfinder site pharmacies taking part in the scheme were <a href=\"\/article\/news\/nhs-could-introduce-performers-list-for-independent-prescribing-pharmacists\">originally planned to launch in January 2023<\/a> but faced complications owing to <a href=\"\/article\/news\/pharmacy-leaders-warn-that-funding-for-independent-prescribing-pilot-programme-could-leave-community-pharmacies-out-of-pocket\">issues with funding<\/a> and implementation.<\/p><p>In <a href=\"https:\/\/www.england.nhs.uk\/long-read\/update-on-independent-prescribing-in-community-pharmacy-pathfinder-programme\/\">August 2024<\/a>, NHS England said that it had transferred funding to ICBs \u201cto support project management, clinical supervision and local evaluation\u201d in June 2024 and that it had asked ICBs \u201cto provide support and leadership to pathfinder sites over the course of the programme (to March 2025)\u201d.<\/p><p>The University of Manchester has been commissioned to report on what has been delivered under the pathfinder programme by early 2025, including the number of sessions held, the number of patients seen, the number of prescriptions issued and the impact on health inequalities.<\/p><p>The university will also be expected to assess the future viability of independent prescribing in community pharmacy and develop recommendations for the service in the future.<\/p><figure class=\"wp-block-embed is-type-rich is-provider-spotify wp-block-embed-spotify\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Spotify Embed: Spotlight: Safety of time-critical medicines\" style=\"border-radius: 12px\" width=\"100%\" height=\"152\" frameborder=\"0\" allowfullscreen allow=\"autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture\" loading=\"lazy\" src=\"https:\/\/open.spotify.com\/embed\/episode\/1yaebHLknS3mXDHFt4Xyci?si=Rq06HuguSLKWd5gFtIvudQ&utm_source=oembed\"><\/iframe>\n<\/div><\/figure>","protected":false},"excerpt":{"rendered":"<p>Well Pharmacy in Keighley, West Yorkshire, has become the first community pharmacy to go live as part of the ‘Independent prescribing in community pharmacy pathfinder programme’, using an electronic prescription service (EPS) specifically designed for the pilot. Under the pathfinder programme, 210 community pharmacies across all 42 integrated care boards (ICBs) in England will trial […]<\/p>\n","protected":false},"featured_media":340862,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"content_for_healthcare_professional":false,"catchline":"Independent prescribing","featured_content_is_featured":false,"display_featured_image":true,"display_featured_image_as_hero":false,"_ml_titleColor":"#000000","_ml_titleFont":"Roboto","_ml_titleFontSize":1.136,"_ml_titleFontWeight":"400","_ml_titleLineHeight":1.3,"_ml_metaColor":"#708090","_ml_metaFont":"Montserrat","_ml_metaFontSize":0.6785,"_ml_metaFontWeight":"400","_ml_metaLineHeight":0.92,"_ml_bodyColor":"#a9a9a9","_ml_bodyFont":"Open Sans","_ml_bodyFontSize":0.85,"_ml_bodyFontWeight":"400","_ml_bodyLineHeight":1.2,"_ml_wooPriceColor":"#666","_ml_wooPriceFont":"Open Sans","_ml_wooPriceFontSize":0.9,"_ml_wooPriceFontWeight":"400","_ml_wooPriceLineHeight":1.27,"_ml_headingColor":"#000","_ml_headingFont":"Merriweather","_ml_headingFontSize":2.02,"_ml_headingFontWeight":"700","_ml_headingLineHeight":1.47,"_mlglobal_userfontcolors":{"headingColorUser":[],"titleColorUser":[],"metaColorUser":[],"bodyColorUser":[],"wooPriceColorUser":[]},"_oasis_is_in_workflow":0,"_oasis_original":0,"_oasis_task_priority":"2normal","premium_content_is_premium":"yes","premium_content_render_panel":true,"stand_first":"Community pharmacy has eagerly awaited the ‘Independent prescribing in community pharmacy pathfinder programme’ after it was announced that, from 2026, all newly qualified pharmacists will become prescribers from the point of registration.","stand_first_render_panel":true,"footnotes":""},"article_tag":[],"section":[27],"news-type":[69],"news-theme":[77],"location":[31],"career-stage":[],"learning-theme":[],"condition-treatment":[1388,56],"career-development":[],"subject":[208,437,686,440,246,166,639,169,1160,271,651,175,303,728],"class_list":["post-340842","news","type-news","status-publish","has-post-thumbnail","hentry","section-news","news-type-latest-news","news-theme-community","location-england","condition-treatment-independent-prescribing","condition-treatment-minor-ailments","subject-community-pharmacy-services","subject-electronic-prescribing","subject-england","subject-england-nhs-structures","subject-healthcare-informatics","subject-healthcare-provision","subject-independent-prescribing","subject-medical-conditions","subject-minor-ailments","subject-nhs","subject-nhs-england","subject-pharmacy-practice","subject-prescribing","subject-uk-healthcare"],"citation":{"data":{"publication":"The Pharmaceutical Journal","issue":"PJ, December 2024, Vol 313, No 7992","location":"313(7992):","doi":"10.1211\/PJ.2024.1.340842"},"rendered":"<i>The Pharmaceutical Journal<\/i>, PJ, December 2024, Vol 313, No 7992;313(7992)::DOI:10.1211\/PJ.2024.1.340842"},"article_extra":{"featured_image":{"src":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/electronicprescribing-927x617.jpg","sizes":{"small":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/electronicprescribing-469x312.jpg 469w","medium":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/electronicprescribing-650x433.jpg 650w","large":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/electronicprescribing-927x617.jpg 927w","xlarge":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/electronicprescribing-728x485.jpg 728w","retina":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/electronicprescribing.jpg 1456w"},"alt_text":"Pharmacist prescribes medicines to a patient on a tablet","caption":"Pathfinder site pharmacies were originally planned to launch in January 2023 but were delayed by problems with funding and implementation ","source_credit":"Shutterstock.com"},"standfirst":"Community pharmacy has eagerly awaited the ‘Independent prescribing in community pharmacy pathfinder programme’ after it was announced that, from 2026, all newly qualified pharmacists will become prescribers from the point of registration.","references":[],"authors":[{"name":"Katherine Price","image":null,"link":"https:\/\/pharmaceutical-journal.com\/author\/katherine-price-2"}],"corresponding_authors":[],"is_promotional":false,"is_supported":false,"is_sponsored":false,"badge":"","article_excerpt":"Community pharmacy has eagerly awaited the ‘Independent prescribing in community pharmacy pathfinder programme’ after it was announced that, from 2026, all newly qualified pharmacists will become prescribers from the point of registration.…","content_partners":[],"modified_datetime":"12 December 2024 3:08 pm","quiz":[]},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>First independent prescribing pathfinder pharmacy goes live using tailored IT system - The Pharmaceutical Journal<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First independent prescribing pathfinder pharmacy goes live using tailored IT system\" \/>\n<meta property=\"og:description\" content=\"Well Pharmacy in Keighley, West Yorkshire, has become the first community pharmacy to go live as part of the ‘Independent prescribing in community pharmacy pathfinder programme’, using an electronic prescription service (EPS) specifically designed for the pilot. Under the pathfinder programme, 210 community pharmacies across all 42 integrated care boards (ICBs) in England will trial […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system\" \/>\n<meta property=\"og:site_name\" content=\"The Pharmaceutical Journal\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/PharmaceuticalJournal\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-12T15:08:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/electronicprescribing.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"7914\" \/>\n\t<meta property=\"og:image:height\" content=\"5263\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@PJOnline_News\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system\",\"url\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system\",\"name\":\"First independent prescribing pathfinder pharmacy goes live using tailored IT system - The Pharmaceutical Journal\",\"isPartOf\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/electronicprescribing.jpg\",\"datePublished\":\"2024-12-12T15:07:58+00:00\",\"dateModified\":\"2024-12-12T15:08:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system#primaryimage\",\"url\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/electronicprescribing.jpg\",\"contentUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/electronicprescribing.jpg\",\"width\":7914,\"height\":5263,\"caption\":\"Pathfinder site pharmacies were originally planned to launch in January 2023 but were delayed by problems with funding and implementation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pharmaceutical-journal.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/pharmaceutical-journal.com\/article\/news\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"First independent prescribing pathfinder pharmacy goes live using tailored IT system\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\",\"url\":\"https:\/\/pharmaceutical-journal.com\/\",\"name\":\"The Pharmaceutical Journal\",\"description\":\"The Pharmaceutical Journal from the Royal Pharmaceutical Society\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"First independent prescribing pathfinder pharmacy goes live using tailored IT system - The Pharmaceutical Journal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system","og_locale":"en_US","og_type":"article","og_title":"First independent prescribing pathfinder pharmacy goes live using tailored IT system","og_description":"Well Pharmacy in Keighley, West Yorkshire, has become the first community pharmacy to go live as part of the ‘Independent prescribing in community pharmacy pathfinder programme’, using an electronic prescription service (EPS) specifically designed for the pilot. Under the pathfinder programme, 210 community pharmacies across all 42 integrated care boards (ICBs) in England will trial […]","og_url":"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system","og_site_name":"The Pharmaceutical Journal","article_publisher":"https:\/\/www.facebook.com\/PharmaceuticalJournal","article_modified_time":"2024-12-12T15:08:00+00:00","og_image":[{"width":7914,"height":5263,"url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/electronicprescribing.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@PJOnline_News","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system","url":"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system","name":"First independent prescribing pathfinder pharmacy goes live using tailored IT system - The Pharmaceutical Journal","isPartOf":{"@id":"https:\/\/pharmaceutical-journal.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system#primaryimage"},"image":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system#primaryimage"},"thumbnailUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/electronicprescribing.jpg","datePublished":"2024-12-12T15:07:58+00:00","dateModified":"2024-12-12T15:08:00+00:00","breadcrumb":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system#primaryimage","url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/electronicprescribing.jpg","contentUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/electronicprescribing.jpg","width":7914,"height":5263,"caption":"Pathfinder site pharmacies were originally planned to launch in January 2023 but were delayed by problems with funding and implementation"},{"@type":"BreadcrumbList","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/first-independent-prescribing-pathfinder-pharmacy-goes-live-using-tailored-it-system#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pharmaceutical-journal.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/pharmaceutical-journal.com\/article\/news"},{"@type":"ListItem","position":3,"name":"First independent prescribing pathfinder pharmacy goes live using tailored IT system"}]},{"@type":"WebSite","@id":"https:\/\/pharmaceutical-journal.com\/#website","url":"https:\/\/pharmaceutical-journal.com\/","name":"The Pharmaceutical Journal","description":"The Pharmaceutical Journal from the Royal Pharmaceutical Society","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340842"}],"collection":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/types\/news"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/comments?post=340842"}],"version-history":[{"count":4,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340842\/revisions"}],"predecessor-version":[{"id":340891,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340842\/revisions\/340891"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media\/340862"}],"wp:attachment":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media?parent=340842"}],"wp:term":[{"taxonomy":"article_tag","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/article_tag?post=340842"},{"taxonomy":"section","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/section?post=340842"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-type?post=340842"},{"taxonomy":"news-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-theme?post=340842"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/location?post=340842"},{"taxonomy":"career-stage","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-stage?post=340842"},{"taxonomy":"learning-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/learning-theme?post=340842"},{"taxonomy":"condition-treatment","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/condition-treatment?post=340842"},{"taxonomy":"career-development","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-development?post=340842"},{"taxonomy":"subject","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/subject?post=340842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":340585,"date":"2024-12-11T09:16:24","date_gmt":"2024-12-11T09:16:24","guid":{"rendered":"https:\/\/pharmaceutical-journal.com\/?post_type=news&p=340585"},"modified":"2024-12-11T09:16:26","modified_gmt":"2024-12-11T09:16:26","slug":"arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show","status":"publish","type":"news","link":"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show","title":{"rendered":"ARRS staff linked to lower prescribing rates in GP practices, study results show"},"content":{"rendered":"<p>The use of additional roles reimbursement scheme (ARRS) in primary care networks (PCNs) is linked to lower prescribing rates and higher patient satisfaction in GP practices, a study has found.<\/p><p>The study, published in the <em><a href=\"https:\/\/bjgp.org\/content\/early\/2024\/12\/09\/BJGP.2024.0196\" data-type=\"link\" data-id=\"https:\/\/bjgp.org\/content\/early\/2024\/12\/09\/BJGP.2024.0196\" target=\"_blank\" rel=\"noreferrer noopener\">British Journal of General Practice<\/a><\/em> on 10 December 2024, looked at data from more than 6,000 general practices in England, including prescribing data and the NHS GP Patient Survey, between January 2018 and December 2021.<\/p><p>The links between ARRS staff and patient satisfaction (\u03b2=3.2,\u00a0<em>P<\/em><0.001) and lower prescribing (\u03b2=\u22120.52,\u00a0<em>P<\/em><0.001) remained even after controlling for patient and practice characteristics.<\/p><p>In particular, lower prescribing for mental health medications, as well as greater patient satisfaction with long-term condition management, was seen in general practices with more ARRS staff.<\/p><p>The paper said: \u201cThe lower prescribing rate could be attributed to the strong emphasis on adherence to guidelines in the training of advanced practitioners and to the availability of a wider range of forms of help, which may reduce the need for prescribed medication.<\/p><p>\u201cThis is particularly consistent with the employment of a high number of clinical pharmacists,\u201d it added.<\/p><p>The ARRS scheme began in England in 2019 and enables PCNs to claim salary costs for <a href=\"https:\/\/www.england.nhs.uk\/long-read\/additional-roles-a-quick-reference-summary\/\" data-type=\"link\" data-id=\"https:\/\/www.england.nhs.uk\/long-read\/additional-roles-a-quick-reference-summary\/\" target=\"_blank\" rel=\"noreferrer noopener\">additional general practice staff<\/a> to support the needs of their local population. As well as clinical pharmacists, ARRS roles include pharmacy technicians, podiatrists and dieticians.<\/p><p>Primary care workforce data, published by NHS Digital in February 2024, showed that <a href=\"\/article\/news\/pharmacists-working-in-primary-care-increase-by-a-quarter-in-a-year\">the number of pharmacists working in primary care had increased by 24.5% in a year<\/a>, from 6,874 full-time equivalents in December 2023 and from 5,522 full-time equivalents at the same time in 2022.<\/p><p>Commenting on the paper, Graham Stretch, president of the Primary Care Pharmacy Association, said: \u201cI am pleased further evidence of the value of ARRS staff has been published, specifically for pharmacists in reducing overprescribing and the demonstration of increased patient satisfaction with the management of their long-term conditions \u2014 a key role where pharmacists can demonstrate their expertise, improving safety.<\/p><p>\u201cThese quality aspects of healthcare delivery, proactive review and avoidance of harms are a win-win-win for all. Patients, as seen here, understand their medications better and have improved satisfaction with their care. Pharmacists are able to deliver deprescribing, structured medication reviews and medication optimisation improving outcomes and reducing harms,\u201d he added.<\/p><p>Danny Bartlett, clinical lead at Kent, Surrey and Sussex Primary Care School and a member of the Royal Pharmaceutical Society\u2019s English Pharmacy Board, said the study was a \u201cgreat indication that ARRS staff are making positive impacts in primary care\u201d.<\/p><p>\u201cThe prescribing figures, I believe, are inherently linked to pharmacists having impacts and roles, which allow them to question why patients are prescribed inappropriate medications and deprescribe them where possible. This is something which obviously was not happening enough before the ARRS roles were in place, due to GP capacity, and is a welcome change,\u201d he added.<\/p><p>In May 2024, concerns were expressed that some pharmacist jobs at PCNs could be at risk, following a change to regulations that meant PCNs could not redistribute unspent ARRS funds between them.<\/p><p>Also in May 2024, speaking at the Clinical Pharmacy Congress, held at ExCeL London, Liz Fidler, senior adviser on pharmacy technicians at NHS England, said that there were plans to <a href=\"\/article\/news\/designated-prescribing-practitioners-in-primary-care-to-be-funded-under-arrs-scheme\" data-type=\"link\" data-id=\"https:\/\/pharmaceutical-journal.com\/article\/news\/designated-prescribing-practitioners-in-primary-care-to-be-funded-under-arrs-scheme\">fund designated prescribing practitioners<\/a> (DPPs) under the ARRS scheme.<\/p><figure class=\"wp-block-embed is-type-rich is-provider-spotify wp-block-embed-spotify\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Spotify Embed: Spotlight: Safety of time-critical medicines\" style=\"border-radius: 12px\" width=\"100%\" height=\"152\" frameborder=\"0\" allowfullscreen allow=\"autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture\" loading=\"lazy\" src=\"https:\/\/open.spotify.com\/embed\/episode\/1yaebHLknS3mXDHFt4Xyci?utm_source=oembed\"><\/iframe>\n<\/div><\/figure>","protected":false},"excerpt":{"rendered":"<p>The use of additional roles reimbursement scheme (ARRS) in primary care networks (PCNs) is linked to lower prescribing rates and higher patient satisfaction in GP practices, a study has found. The study, published in the British Journal of General Practice on 10 December 2024, looked at data from more than 6,000 general practices in England, […]<\/p>\n","protected":false},"featured_media":340665,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"content_for_healthcare_professional":false,"catchline":"Prescribing","featured_content_is_featured":false,"display_featured_image":true,"display_featured_image_as_hero":false,"_ml_titleColor":"#000000","_ml_titleFont":"Roboto","_ml_titleFontSize":1.136,"_ml_titleFontWeight":"400","_ml_titleLineHeight":1.3,"_ml_metaColor":"#708090","_ml_metaFont":"Montserrat","_ml_metaFontSize":0.6785,"_ml_metaFontWeight":"400","_ml_metaLineHeight":0.92,"_ml_bodyColor":"#a9a9a9","_ml_bodyFont":"Open Sans","_ml_bodyFontSize":0.85,"_ml_bodyFontWeight":"400","_ml_bodyLineHeight":1.2,"_ml_wooPriceColor":"#666","_ml_wooPriceFont":"Open Sans","_ml_wooPriceFontSize":0.9,"_ml_wooPriceFontWeight":"400","_ml_wooPriceLineHeight":1.27,"_ml_headingColor":"#000","_ml_headingFont":"Merriweather","_ml_headingFontSize":2.02,"_ml_headingFontWeight":"700","_ml_headingLineHeight":1.47,"_mlglobal_userfontcolors":{"headingColorUser":[],"titleColorUser":[],"metaColorUser":[],"bodyColorUser":[],"wooPriceColorUser":[]},"_oasis_is_in_workflow":0,"_oasis_original":0,"_oasis_task_priority":"2normal","premium_content_is_premium":"yes","premium_content_render_panel":true,"stand_first":"Lower levels of prescribing could be attributed to the high number of pharmacists employed under the additional roles reimbursement scheme, the paper says.","stand_first_render_panel":true,"footnotes":""},"article_tag":[],"section":[27],"news-type":[69],"news-theme":[79],"location":[31],"career-stage":[],"learning-theme":[],"condition-treatment":[],"career-development":[],"subject":[704,625,639,651,659,527,296,303,549],"class_list":["post-340585","news","type-news","status-publish","has-post-thumbnail","hentry","section-news","news-type-latest-news","news-theme-general-practice","location-england","subject-clinical-pharmacist","subject-gp","subject-independent-prescribing","subject-nhs-england","subject-pharmacist","subject-pharmacy","subject-pharmacy-sectors","subject-prescribing","subject-primary-care"],"citation":{"data":{"publication":"The Pharmaceutical Journal","issue":"PJ, December 2024, Vol 313, No 7992","location":"313(7992):","doi":"10.1211\/PJ.2024.1.340585"},"rendered":"<i>The Pharmaceutical Journal<\/i>, PJ, December 2024, Vol 313, No 7992;313(7992)::DOI:10.1211\/PJ.2024.1.340585"},"article_extra":{"featured_image":{"src":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/lowerprescribingrates-927x617.jpg","sizes":{"small":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/lowerprescribingrates-469x312.jpg 469w","medium":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/lowerprescribingrates-650x433.jpg 650w","large":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/lowerprescribingrates-927x617.jpg 927w","xlarge":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/lowerprescribingrates-728x485.jpg 728w","retina":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/lowerprescribingrates-e1733851810400.jpg 1456w"},"alt_text":"Pharmacist writes a prescription","caption":"The ARRS scheme, which launched in England in 2019, enables PCNs to claim salary costs for additional general practice staff, including pharmacists, to support their local population","source_credit":"Shutterstock.com"},"standfirst":"Lower levels of prescribing could be attributed to the high number of pharmacists employed under the additional roles reimbursement scheme, the paper says.","references":[],"authors":[{"name":"Corrinne Burns","image":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2021\/01\/1705-40x40.jpg","link":"https:\/\/pharmaceutical-journal.com\/author\/corrinne-burns"}],"corresponding_authors":[],"is_promotional":false,"is_supported":false,"is_sponsored":false,"badge":"","article_excerpt":"Lower levels of prescribing could be attributed to the high number of pharmacists employed under the additional roles reimbursement scheme, the paper says.…","content_partners":[],"modified_datetime":"11 December 2024 9:16 am","quiz":[]},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ARRS staff linked to lower prescribing rates in GP practices, study results show - The Pharmaceutical Journal<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ARRS staff linked to lower prescribing rates in GP practices, study results show\" \/>\n<meta property=\"og:description\" content=\"The use of additional roles reimbursement scheme (ARRS) in primary care networks (PCNs) is linked to lower prescribing rates and higher patient satisfaction in GP practices, a study has found. The study, published in the British Journal of General Practice on 10 December 2024, looked at data from more than 6,000 general practices in England, […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show\" \/>\n<meta property=\"og:site_name\" content=\"The Pharmaceutical Journal\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/PharmaceuticalJournal\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-11T09:16:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/lowerprescribingrates-e1733851810400.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"681\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@PJOnline_News\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show\",\"url\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show\",\"name\":\"ARRS staff linked to lower prescribing rates in GP practices, study results show - The Pharmaceutical Journal\",\"isPartOf\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/lowerprescribingrates-e1733851810400.jpg\",\"datePublished\":\"2024-12-11T09:16:24+00:00\",\"dateModified\":\"2024-12-11T09:16:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show#primaryimage\",\"url\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/lowerprescribingrates-e1733851810400.jpg\",\"contentUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/lowerprescribingrates-e1733851810400.jpg\",\"width\":1024,\"height\":681,\"caption\":\"The ARRS scheme, which launched in England in 2019, enables PCNs to claim salary costs for additional general practice staff, including pharmacists, to support their local population\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pharmaceutical-journal.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/pharmaceutical-journal.com\/article\/news\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"ARRS staff linked to lower prescribing rates in GP practices, study results show\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\",\"url\":\"https:\/\/pharmaceutical-journal.com\/\",\"name\":\"The Pharmaceutical Journal\",\"description\":\"The Pharmaceutical Journal from the Royal Pharmaceutical Society\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ARRS staff linked to lower prescribing rates in GP practices, study results show - The Pharmaceutical Journal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show","og_locale":"en_US","og_type":"article","og_title":"ARRS staff linked to lower prescribing rates in GP practices, study results show","og_description":"The use of additional roles reimbursement scheme (ARRS) in primary care networks (PCNs) is linked to lower prescribing rates and higher patient satisfaction in GP practices, a study has found. The study, published in the British Journal of General Practice on 10 December 2024, looked at data from more than 6,000 general practices in England, […]","og_url":"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show","og_site_name":"The Pharmaceutical Journal","article_publisher":"https:\/\/www.facebook.com\/PharmaceuticalJournal","article_modified_time":"2024-12-11T09:16:26+00:00","og_image":[{"width":1024,"height":681,"url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/lowerprescribingrates-e1733851810400.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@PJOnline_News","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show","url":"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show","name":"ARRS staff linked to lower prescribing rates in GP practices, study results show - The Pharmaceutical Journal","isPartOf":{"@id":"https:\/\/pharmaceutical-journal.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show#primaryimage"},"image":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show#primaryimage"},"thumbnailUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/lowerprescribingrates-e1733851810400.jpg","datePublished":"2024-12-11T09:16:24+00:00","dateModified":"2024-12-11T09:16:26+00:00","breadcrumb":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show#primaryimage","url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/lowerprescribingrates-e1733851810400.jpg","contentUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/lowerprescribingrates-e1733851810400.jpg","width":1024,"height":681,"caption":"The ARRS scheme, which launched in England in 2019, enables PCNs to claim salary costs for additional general practice staff, including pharmacists, to support their local population"},{"@type":"BreadcrumbList","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/arrs-staff-linked-to-lower-prescribing-rates-in-gp-practices-study-results-show#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pharmaceutical-journal.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/pharmaceutical-journal.com\/article\/news"},{"@type":"ListItem","position":3,"name":"ARRS staff linked to lower prescribing rates in GP practices, study results show"}]},{"@type":"WebSite","@id":"https:\/\/pharmaceutical-journal.com\/#website","url":"https:\/\/pharmaceutical-journal.com\/","name":"The Pharmaceutical Journal","description":"The Pharmaceutical Journal from the Royal Pharmaceutical Society","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340585"}],"collection":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/types\/news"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/comments?post=340585"}],"version-history":[{"count":4,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340585\/revisions"}],"predecessor-version":[{"id":340733,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340585\/revisions\/340733"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media\/340665"}],"wp:attachment":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media?parent=340585"}],"wp:term":[{"taxonomy":"article_tag","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/article_tag?post=340585"},{"taxonomy":"section","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/section?post=340585"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-type?post=340585"},{"taxonomy":"news-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-theme?post=340585"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/location?post=340585"},{"taxonomy":"career-stage","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-stage?post=340585"},{"taxonomy":"learning-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/learning-theme?post=340585"},{"taxonomy":"condition-treatment","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/condition-treatment?post=340585"},{"taxonomy":"career-development","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-development?post=340585"},{"taxonomy":"subject","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/subject?post=340585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":340363,"date":"2024-12-10T15:38:55","date_gmt":"2024-12-10T15:38:55","guid":{"rendered":"https:\/\/pharmaceutical-journal.com\/?post_type=news&p=340363"},"modified":"2024-12-10T15:38:57","modified_gmt":"2024-12-10T15:38:57","slug":"access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025","status":"publish","type":"news","link":"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025","title":{"rendered":"Access to PrEP from community pharmacies could be piloted from autumn 2025"},"content":{"rendered":"<p>HIV pre-exposure prophylaxis (PrEP) could be provided in community pharmacies in Wales from autumn 2025, the Welsh government has told <em>The Pharmaceutical Journal<\/em>.<\/p><p>In a <a href=\"https:\/\/www.gov.wales\/written-statement-hiv-action-plan-wales-2023-26-annual-progress-statement\" target=\"_blank\" rel=\"noreferrer noopener\">written update<\/a> on the \u2018<a href=\"https:\/\/www.gov.wales\/sites\/default\/files\/publications\/2023-03\/hiv-action-plan-for-wales-2023-to-2026.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">HIV Action Plan for Wales 2023\u20132026<\/a>\u2019, published on 18 November 2024, Jeremy Miles, cabinet secretary for health and social care, said that Wales was making \u201cencouraging progress\u201d towards the Welsh government’s target of zero new HIV transmissions by 2030, with screening and PrEP uptake increasing.<\/p><p>Miles added: \u201cAlthough the use of PrEP continues to grow, we can make access even easier. PrEP is predominantly used by gay, bisexual and other men who have sex with men but much less so by those in other at-risk groups. Making improvements to access will help address this.<\/p><p>\u201cA model providing more convenient access to PrEP in the community will be piloted and an awareness-raising campaign will run in the spring so all those at risk know about PrEP and how to access it.\u201d<\/p><p>A spokesperson for the Welsh government told <em>The Pharmaceutical Journal<\/em> that the model would likely be piloted from autumn 2025 and that it would consider pharmacist involvement in provision.<\/p><p>\u201cWe are working with health boards to finalise plans to pilot a model, which will provide more convenient access to PrEP in the community,\u201d they said.<\/p><p>\u201cThe pilot, which we anticipate will begin in autumn 2025, will include exploring the role pharmacists providing Wales\u2019 national pharmacist independent prescribing service might play in making PrEP more accessible.\u201d<\/p><p>In England, plans to provide PrEP in the community, including in pharmacies, have been in discussion since the publication of the country\u2019s <a href=\"https:\/\/www.gov.uk\/government\/publications\/towards-zero-the-hiv-action-plan-for-england-2022-to-2025\" target=\"_blank\" rel=\"noreferrer noopener\">HIV action plan in 2021<\/a>.<\/p><p>A <a href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/pilots-to-provide-prep-via-pharmacies-only-possible-future-opportunities-report-warns\">roadmap for providing PrEP in the community<\/a>, commissioned by the Department of Health and Social Care (DHSC) and produced by the independent HIV Action Plan Implementation Steering Group, was published in February 2024, <a href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/roadmap-to-provide-prep-via-community-pharmacies-will-be-ready-by-the-end-of-the-year-government-says\">after originally being promised for the end of 2023<\/a>.<\/p><p>The roadmap said that PrEP pilots were only being considered as \u201cpossible future opportunities\u201d, which it described as \u201cconcerning\u201d.<\/p><p>In response to a question on the progress of the pilots in England, a spokesperson for the DHSC told <em>The Pharmaceutical Journal<\/em>: \u201cWe are exploring opportunities to deliver PrEP in settings outside sexual health services to improve access, including considering online PrEP provision and PrEP in pharmacies. <\/p><p>\u201cMore widely, this government is committed to shifting the focus of healthcare from hospitals to the community. This includes expanding the role of pharmacies by better utilising the skills of pharmacists, pharmacy technicians and making prescribing part of the services delivered by community pharmacists.\u201d<\/p><p>Commenting on the possibility of PrEP availability in pharmacies in Wales, Daniel Fluskey, director of policy, research and influencing at the National AIDS Trust, said: \u201cTo reach the goal of ending new HIV transmissions by 2030 that the Welsh government has committed to, everyone who can benefit from PrEP must be able to access it easily. <\/p><p>\u201cWe know that currently too many people can’t access PrEP, so it is critical that new and creative approaches are taken. Allowing people to get PrEP from their local pharmacy can widen access and convenience for people, as well as ease some of the pressure that sexual health services are experiencing, so we warmly welcome this pilot scheme, which we hope will be successful and bring us a step closer to achieving these aims.\u201d<\/p><figure class=\"wp-block-embed is-type-rich is-provider-spotify wp-block-embed-spotify\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Spotify Embed: Spotlight: Safety of time-critical medicines\" style=\"border-radius: 12px\" width=\"100%\" height=\"152\" frameborder=\"0\" allowfullscreen allow=\"autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture\" loading=\"lazy\" src=\"https:\/\/open.spotify.com\/embed\/episode\/1yaebHLknS3mXDHFt4Xyci?utm_source=oembed\"><\/iframe>\n<\/div><\/figure>","protected":false},"excerpt":{"rendered":"<p>HIV pre-exposure prophylaxis (PrEP) could be provided in community pharmacies in Wales from autumn 2025, the Welsh government has told The Pharmaceutical Journal. In a written update on the \u2018HIV Action Plan for Wales 2023\u20132026\u2019, published on 18 November 2024, Jeremy Miles, cabinet secretary for health and social care, said that Wales was making \u201cencouraging […]<\/p>\n","protected":false},"featured_media":340623,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"content_for_healthcare_professional":false,"catchline":"HIV","featured_content_is_featured":false,"display_featured_image":true,"display_featured_image_as_hero":false,"_ml_titleColor":"#000000","_ml_titleFont":"Roboto","_ml_titleFontSize":1.136,"_ml_titleFontWeight":"400","_ml_titleLineHeight":1.3,"_ml_metaColor":"#708090","_ml_metaFont":"Montserrat","_ml_metaFontSize":0.6785,"_ml_metaFontWeight":"400","_ml_metaLineHeight":0.92,"_ml_bodyColor":"#a9a9a9","_ml_bodyFont":"Open Sans","_ml_bodyFontSize":0.85,"_ml_bodyFontWeight":"400","_ml_bodyLineHeight":1.2,"_ml_wooPriceColor":"#666","_ml_wooPriceFont":"Open Sans","_ml_wooPriceFontSize":0.9,"_ml_wooPriceFontWeight":"400","_ml_wooPriceLineHeight":1.27,"_ml_headingColor":"#000","_ml_headingFont":"Merriweather","_ml_headingFontSize":2.02,"_ml_headingFontWeight":"700","_ml_headingLineHeight":1.47,"_mlglobal_userfontcolors":{"headingColorUser":[],"titleColorUser":[],"metaColorUser":[],"bodyColorUser":[],"wooPriceColorUser":[]},"_oasis_is_in_workflow":0,"_oasis_original":0,"_oasis_task_priority":"2normal","premium_content_is_premium":"yes","premium_content_render_panel":true,"stand_first":"Exclusive: The Welsh government said it would explore pharmacist involvement in a pilot scheme designed to improve access to pre-exposure prophylaxis in the community.","stand_first_render_panel":true,"footnotes":""},"article_tag":[],"section":[27],"news-type":[69],"news-theme":[77],"location":[],"career-stage":[],"learning-theme":[],"condition-treatment":[65],"career-development":[],"subject":[147,633,252,169,170,596],"class_list":["post-340363","news","type-news","status-publish","has-post-thumbnail","hentry","section-news","news-type-latest-news","news-theme-community","condition-treatment-sexual-health","subject-drug","subject-hiv","subject-infectious-diseases","subject-medical-conditions","subject-medicines","subject-viral-infections"],"citation":{"data":{"publication":"The Pharmaceutical Journal","issue":"PJ, December 2024, Vol 313, No 7992","location":"313(7992):","doi":"10.1211\/PJ.2024.1.340363"},"rendered":"<i>The Pharmaceutical Journal<\/i>, PJ, December 2024, Vol 313, No 7992;313(7992)::DOI:10.1211\/PJ.2024.1.340363"},"article_extra":{"featured_image":{"src":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_2419801725-927x617.jpg","sizes":{"small":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_2419801725-469x312.jpg 469w","medium":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_2419801725-650x433.jpg 650w","large":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_2419801725-927x617.jpg 927w","xlarge":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_2419801725-728x485.jpg 728w","retina":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_2419801725-1456x967.jpg 1456w"},"alt_text":"Man pours PrEP tablets into his hand","caption":"The accessibility of pre-exposure prophylaxis aims to help achieve the Welsh government's target of zero new HIV transmissions by 2030","source_credit":"Shutterstock.com"},"standfirst":"Exclusive: The Welsh government said it would explore pharmacist involvement in a pilot scheme designed to improve access to pre-exposure prophylaxis in the community.","references":[],"authors":[{"name":"Sophie Willis","image":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2021\/01\/2430-40x40.jpg","link":"https:\/\/pharmaceutical-journal.com\/author\/sophie-willis"}],"corresponding_authors":[],"is_promotional":false,"is_supported":false,"is_sponsored":false,"badge":"","article_excerpt":"Exclusive: The Welsh government said it would explore pharmacist involvement in a pilot scheme designed to improve access to pre-exposure prophylaxis in the community.…","content_partners":[],"modified_datetime":"10 December 2024 3:38 pm","quiz":[]},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Access to PrEP from community pharmacies could be piloted from autumn 2025 - The Pharmaceutical Journal<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Access to PrEP from community pharmacies could be piloted from autumn 2025\" \/>\n<meta property=\"og:description\" content=\"HIV pre-exposure prophylaxis (PrEP) could be provided in community pharmacies in Wales from autumn 2025, the Welsh government has told The Pharmaceutical Journal. In a written update on the \u2018HIV Action Plan for Wales 2023\u20132026\u2019, published on 18 November 2024, Jeremy Miles, cabinet secretary for health and social care, said that Wales was making \u201cencouraging […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025\" \/>\n<meta property=\"og:site_name\" content=\"The Pharmaceutical Journal\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/PharmaceuticalJournal\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-10T15:38:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_2419801725-scaled-e1733844860628.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@PJOnline_News\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025\",\"url\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025\",\"name\":\"Access to PrEP from community pharmacies could be piloted from autumn 2025 - The Pharmaceutical Journal\",\"isPartOf\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_2419801725-scaled-e1733844860628.jpg\",\"datePublished\":\"2024-12-10T15:38:55+00:00\",\"dateModified\":\"2024-12-10T15:38:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025#primaryimage\",\"url\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_2419801725-scaled-e1733844860628.jpg\",\"contentUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_2419801725-scaled-e1733844860628.jpg\",\"width\":1024,\"height\":683,\"caption\":\"The accessibility of pre-exposure prophylaxis aims to help achieve the Welsh government's target of zero new HIV transmissions by 2030\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pharmaceutical-journal.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/pharmaceutical-journal.com\/article\/news\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Access to PrEP from community pharmacies could be piloted from autumn 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\",\"url\":\"https:\/\/pharmaceutical-journal.com\/\",\"name\":\"The Pharmaceutical Journal\",\"description\":\"The Pharmaceutical Journal from the Royal Pharmaceutical Society\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Access to PrEP from community pharmacies could be piloted from autumn 2025 - The Pharmaceutical Journal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025","og_locale":"en_US","og_type":"article","og_title":"Access to PrEP from community pharmacies could be piloted from autumn 2025","og_description":"HIV pre-exposure prophylaxis (PrEP) could be provided in community pharmacies in Wales from autumn 2025, the Welsh government has told The Pharmaceutical Journal. In a written update on the \u2018HIV Action Plan for Wales 2023\u20132026\u2019, published on 18 November 2024, Jeremy Miles, cabinet secretary for health and social care, said that Wales was making \u201cencouraging […]","og_url":"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025","og_site_name":"The Pharmaceutical Journal","article_publisher":"https:\/\/www.facebook.com\/PharmaceuticalJournal","article_modified_time":"2024-12-10T15:38:57+00:00","og_image":[{"width":1024,"height":683,"url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_2419801725-scaled-e1733844860628.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@PJOnline_News","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025","url":"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025","name":"Access to PrEP from community pharmacies could be piloted from autumn 2025 - The Pharmaceutical Journal","isPartOf":{"@id":"https:\/\/pharmaceutical-journal.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025#primaryimage"},"image":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025#primaryimage"},"thumbnailUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_2419801725-scaled-e1733844860628.jpg","datePublished":"2024-12-10T15:38:55+00:00","dateModified":"2024-12-10T15:38:57+00:00","breadcrumb":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025#primaryimage","url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_2419801725-scaled-e1733844860628.jpg","contentUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_2419801725-scaled-e1733844860628.jpg","width":1024,"height":683,"caption":"The accessibility of pre-exposure prophylaxis aims to help achieve the Welsh government's target of zero new HIV transmissions by 2030"},{"@type":"BreadcrumbList","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/access-to-prep-from-community-pharmacies-could-be-piloted-from-autumn-2025#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pharmaceutical-journal.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/pharmaceutical-journal.com\/article\/news"},{"@type":"ListItem","position":3,"name":"Access to PrEP from community pharmacies could be piloted from autumn 2025"}]},{"@type":"WebSite","@id":"https:\/\/pharmaceutical-journal.com\/#website","url":"https:\/\/pharmaceutical-journal.com\/","name":"The Pharmaceutical Journal","description":"The Pharmaceutical Journal from the Royal Pharmaceutical Society","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340363"}],"collection":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/types\/news"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/comments?post=340363"}],"version-history":[{"count":4,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340363\/revisions"}],"predecessor-version":[{"id":340661,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340363\/revisions\/340661"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media\/340623"}],"wp:attachment":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media?parent=340363"}],"wp:term":[{"taxonomy":"article_tag","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/article_tag?post=340363"},{"taxonomy":"section","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/section?post=340363"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-type?post=340363"},{"taxonomy":"news-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-theme?post=340363"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/location?post=340363"},{"taxonomy":"career-stage","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-stage?post=340363"},{"taxonomy":"learning-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/learning-theme?post=340363"},{"taxonomy":"condition-treatment","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/condition-treatment?post=340363"},{"taxonomy":"career-development","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-development?post=340363"},{"taxonomy":"subject","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/subject?post=340363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":340494,"date":"2024-12-10T12:36:50","date_gmt":"2024-12-10T12:36:50","guid":{"rendered":"https:\/\/pharmaceutical-journal.com\/?post_type=news&p=340494"},"modified":"2024-12-10T12:36:52","modified_gmt":"2024-12-10T12:36:52","slug":"margaret-little-1933-2024","status":"publish","type":"news","link":"https:\/\/pharmaceutical-journal.com\/article\/news\/margaret-little-1933-2024","title":{"rendered":"Margaret Little (1933\u20132024)"},"content":{"rendered":"<p>On 28 March 2024, Margaret Little MPharmS, aged 90 years, of London. Ms Little registered with the Society in 1957.<\/p>","protected":false},"excerpt":{"rendered":"<p>On 28 March 2024, Margaret Little MPharmS, aged 90 years, of London. Ms Little registered with the Society in 1957.<\/p>\n","protected":false},"featured_media":0,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"content_for_healthcare_professional":false,"catchline":"Death notice","featured_content_is_featured":false,"display_featured_image":true,"display_featured_image_as_hero":false,"_ml_titleColor":"#000000","_ml_titleFont":"Roboto","_ml_titleFontSize":1.136,"_ml_titleFontWeight":"400","_ml_titleLineHeight":1.3,"_ml_metaColor":"#708090","_ml_metaFont":"Montserrat","_ml_metaFontSize":0.6785,"_ml_metaFontWeight":"400","_ml_metaLineHeight":0.92,"_ml_bodyColor":"#a9a9a9","_ml_bodyFont":"Open Sans","_ml_bodyFontSize":0.85,"_ml_bodyFontWeight":"400","_ml_bodyLineHeight":1.2,"_ml_wooPriceColor":"#666","_ml_wooPriceFont":"Open Sans","_ml_wooPriceFontSize":0.9,"_ml_wooPriceFontWeight":"400","_ml_wooPriceLineHeight":1.27,"_ml_headingColor":"#000","_ml_headingFont":"Merriweather","_ml_headingFontSize":2.02,"_ml_headingFontWeight":"700","_ml_headingLineHeight":1.47,"_mlglobal_userfontcolors":{"headingColorUser":[],"titleColorUser":[],"metaColorUser":[],"bodyColorUser":[],"wooPriceColorUser":[]},"_oasis_is_in_workflow":0,"_oasis_original":0,"_oasis_task_priority":"","premium_content_is_premium":"yes","premium_content_render_panel":true,"stand_first":"","stand_first_render_panel":true,"footnotes":""},"article_tag":[],"section":[27],"news-type":[1351],"news-theme":[],"location":[],"career-stage":[],"learning-theme":[],"condition-treatment":[],"career-development":[],"subject":[],"class_list":["post-340494","news","type-news","status-publish","hentry","section-news","news-type-tributes"],"citation":{"data":{"publication":"The Pharmaceutical Journal","issue":"PJ, December 2024, Vol 313, No 7992","location":"313(7992):","doi":"10.1211\/PJ.2024.1.340494"},"rendered":"<i>The Pharmaceutical Journal<\/i>, PJ, December 2024, Vol 313, No 7992;313(7992)::DOI:10.1211\/PJ.2024.1.340494"},"article_extra":{"featured_image":[],"standfirst":"","references":[],"authors":[],"corresponding_authors":[],"is_promotional":false,"is_supported":false,"is_sponsored":false,"badge":"","article_excerpt":"On 28 March 2024, Margaret Little MPharmS, aged 90 years, of London. Ms Little registered with the Society in 1957.…","content_partners":[],"modified_datetime":"10 December 2024 12:36 pm","quiz":[]},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Margaret Little (1933\u20132024) - The Pharmaceutical Journal<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/margaret-little-1933-2024\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Margaret Little (1933\u20132024)\" \/>\n<meta property=\"og:description\" content=\"On 28 March 2024, Margaret Little MPharmS, aged 90 years, of London. Ms Little registered with the Society in 1957.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharmaceutical-journal.com\/article\/news\/margaret-little-1933-2024\" \/>\n<meta property=\"og:site_name\" content=\"The Pharmaceutical Journal\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/PharmaceuticalJournal\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-10T12:36:52+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@PJOnline_News\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/margaret-little-1933-2024\",\"url\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/margaret-little-1933-2024\",\"name\":\"Margaret Little (1933\u20132024) - The Pharmaceutical Journal\",\"isPartOf\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\"},\"datePublished\":\"2024-12-10T12:36:50+00:00\",\"dateModified\":\"2024-12-10T12:36:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/margaret-little-1933-2024#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pharmaceutical-journal.com\/article\/news\/margaret-little-1933-2024\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/margaret-little-1933-2024#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pharmaceutical-journal.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/pharmaceutical-journal.com\/article\/news\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Margaret Little (1933\u20132024)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\",\"url\":\"https:\/\/pharmaceutical-journal.com\/\",\"name\":\"The Pharmaceutical Journal\",\"description\":\"The Pharmaceutical Journal from the Royal Pharmaceutical Society\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Margaret Little (1933\u20132024) - The Pharmaceutical Journal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharmaceutical-journal.com\/article\/news\/margaret-little-1933-2024","og_locale":"en_US","og_type":"article","og_title":"Margaret Little (1933\u20132024)","og_description":"On 28 March 2024, Margaret Little MPharmS, aged 90 years, of London. Ms Little registered with the Society in 1957.","og_url":"https:\/\/pharmaceutical-journal.com\/article\/news\/margaret-little-1933-2024","og_site_name":"The Pharmaceutical Journal","article_publisher":"https:\/\/www.facebook.com\/PharmaceuticalJournal","article_modified_time":"2024-12-10T12:36:52+00:00","twitter_card":"summary_large_image","twitter_site":"@PJOnline_News","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/margaret-little-1933-2024","url":"https:\/\/pharmaceutical-journal.com\/article\/news\/margaret-little-1933-2024","name":"Margaret Little (1933\u20132024) - The Pharmaceutical Journal","isPartOf":{"@id":"https:\/\/pharmaceutical-journal.com\/#website"},"datePublished":"2024-12-10T12:36:50+00:00","dateModified":"2024-12-10T12:36:52+00:00","breadcrumb":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/margaret-little-1933-2024#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharmaceutical-journal.com\/article\/news\/margaret-little-1933-2024"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/margaret-little-1933-2024#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pharmaceutical-journal.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/pharmaceutical-journal.com\/article\/news"},{"@type":"ListItem","position":3,"name":"Margaret Little (1933\u20132024)"}]},{"@type":"WebSite","@id":"https:\/\/pharmaceutical-journal.com\/#website","url":"https:\/\/pharmaceutical-journal.com\/","name":"The Pharmaceutical Journal","description":"The Pharmaceutical Journal from the Royal Pharmaceutical Society","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340494"}],"collection":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/types\/news"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/comments?post=340494"}],"version-history":[{"count":2,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340494\/revisions"}],"predecessor-version":[{"id":340498,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340494\/revisions\/340498"}],"wp:attachment":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media?parent=340494"}],"wp:term":[{"taxonomy":"article_tag","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/article_tag?post=340494"},{"taxonomy":"section","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/section?post=340494"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-type?post=340494"},{"taxonomy":"news-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-theme?post=340494"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/location?post=340494"},{"taxonomy":"career-stage","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-stage?post=340494"},{"taxonomy":"learning-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/learning-theme?post=340494"},{"taxonomy":"condition-treatment","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/condition-treatment?post=340494"},{"taxonomy":"career-development","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-development?post=340494"},{"taxonomy":"subject","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/subject?post=340494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":340358,"date":"2024-12-10T12:23:20","date_gmt":"2024-12-10T12:23:20","guid":{"rendered":"https:\/\/pharmaceutical-journal.com\/?post_type=news&p=340358"},"modified":"2024-12-10T12:23:22","modified_gmt":"2024-12-10T12:23:22","slug":"acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body","status":"publish","type":"news","link":"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body","title":{"rendered":"Hospitals should review pharmacy support in emergency departments, says health safety investigation body"},"content":{"rendered":"<p>Hospitals should look at the pharmacy support available to staff in emergency departments, a report from the <a href=\"https:\/\/www.hssib.org.uk\/patient-safety-investigations\/medication-related-harm\/investigation-report\/\" data-type=\"link\" data-id=\"https:\/\/www.hssib.org.uk\/patient-safety-investigations\/medication-related-harm\/investigation-report\/\" target=\"_blank\" rel=\"noreferrer noopener\">Health Services Safety Investigations Body<\/a> (HSSIB) has said.<\/p><p>The recommendation is from a report that was produced in response to the death of a patient with Parkinson’s disease, who was admitted to an unidentified hospital and spent three days in the emergency department (ED). In that time, he should have received 18 doses of a time-critical Parkinson\u2019s medicine, the report states, but seven doses were not given and three doses were given late.<\/p><p>The patient deteriorated and later died, with identified causes of death including bronchopneumonia, Parkinson\u2019s disease and the frailty of old age.<\/p><p>The report noted that the ED had no dedicated pharmacy support to help staff in providing care to patients who required time-critical medicines. It also said that in the ED, there were \u201cno defined roles or responsibilities\u201d to ensure patients who required time-critical medicines were identified and received a prescription as soon as possible.<\/p><p>In addition, the report says the ED previously had a dedicated ED pharmacist, and staff said that at that time they felt supported with medicines and prescribing. It added that \u201cthe funding for this post was temporary, and when the funding was no longer available, the post was made redundant\u201d.<\/p><p>The report also found that the hospital’s electronic prescribing (ePMA) system \u201cdid not include a function to alert staff about patients who required time-critical medications to be prescribed or administered\u201d.<\/p><p>As well as asking EDs to look at pharmacy support, the report also asks hospitals to consider how they ensure that patients who need time-critical medicines are identified as soon as possible upon admission. It also says hospitals should consider how their ePMA system helps to alert staff to patients who need time-critical medicines.<\/p><p>In its report \u2018<a href=\"https:\/\/www.parkinsons.org.uk\/sites\/default\/files\/2023-09\/CS4006%20Get%20it%20on%20time%20policy%20report_Web%20Version.pdf\" data-type=\"link\" data-id=\"https:\/\/www.parkinsons.org.uk\/sites\/default\/files\/2023-09\/CS4006%20Get%20it%20on%20time%20policy%20report_Web%20Version.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Every minute counts<\/a>\u2019, published in September 2023, charity Parkinson\u2019s UK, said that 58% of people with Parkinson’s disease who were admitted to hospital in England did not receive their medicines on time, every time.<\/p><p>In December 2023, a <a href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/all-emergency-departments-must-have-dedicated-pharmacist-royal-college-and-ukcpa-say\" data-type=\"link\" data-id=\"https:\/\/pharmaceutical-journal.com\/article\/news\/all-emergency-departments-must-have-dedicated-pharmacist-royal-college-and-ukcpa-say\">joint statement from the Royal College of Emergency Medicine (RCEM) and the UK Clinical Pharmacy Association<\/a> said that all hospital EDs in the UK \u201cmust have a dedicated pharmacist\u201d and a pharmacy technician, and that the pharmacy service should be available seven days per week.<\/p><p>Commenting generally \u2014 not on the case investigated by the HSSIB \u2014 a spokesperson for the RCEM told <em>The Pharmaceutical Journal<\/em> that it \u201crecommends the use of dedicated ED pharmacists and pharmacy services to work as part of the multidisciplinary team to help support the safe and efficient delivery of care to patients in the ED, as well as in clinical decision units\/observation wards\u201d.<\/p><figure class=\"wp-block-embed is-type-rich is-provider-spotify wp-block-embed-spotify\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Spotify Embed: Spotlight: Safety of time-critical medicines\" style=\"border-radius: 12px\" width=\"100%\" height=\"152\" frameborder=\"0\" allowfullscreen allow=\"autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture\" loading=\"lazy\" src=\"https:\/\/open.spotify.com\/embed\/episode\/1yaebHLknS3mXDHFt4Xyci?si=p4sGAwutSe-d58Wofxt_NQ&utm_source=oembed\"><\/iframe>\n<\/div><\/figure>","protected":false},"excerpt":{"rendered":"<p>Hospitals should look at the pharmacy support available to staff in emergency departments, a report from the Health Services Safety Investigations Body (HSSIB) has said. The recommendation is from a report that was produced in response to the death of a patient with Parkinson’s disease, who was admitted to an unidentified hospital and spent three […]<\/p>\n","protected":false},"featured_media":340502,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"content_for_healthcare_professional":false,"catchline":"Hospital","featured_content_is_featured":false,"display_featured_image":true,"display_featured_image_as_hero":false,"_ml_titleColor":"#000000","_ml_titleFont":"Roboto","_ml_titleFontSize":1.136,"_ml_titleFontWeight":"400","_ml_titleLineHeight":1.3,"_ml_metaColor":"#708090","_ml_metaFont":"Montserrat","_ml_metaFontSize":0.6785,"_ml_metaFontWeight":"400","_ml_metaLineHeight":0.92,"_ml_bodyColor":"#a9a9a9","_ml_bodyFont":"Open Sans","_ml_bodyFontSize":0.85,"_ml_bodyFontWeight":"400","_ml_bodyLineHeight":1.2,"_ml_wooPriceColor":"#666","_ml_wooPriceFont":"Open Sans","_ml_wooPriceFontSize":0.9,"_ml_wooPriceFontWeight":"400","_ml_wooPriceLineHeight":1.27,"_ml_headingColor":"#000","_ml_headingFont":"Merriweather","_ml_headingFontSize":2.02,"_ml_headingFontWeight":"700","_ml_headingLineHeight":1.47,"_mlglobal_userfontcolors":{"headingColorUser":[],"titleColorUser":[],"metaColorUser":[],"bodyColorUser":[],"wooPriceColorUser":[]},"_oasis_is_in_workflow":0,"_oasis_original":0,"_oasis_task_priority":"2normal","premium_content_is_premium":"yes","premium_content_render_panel":true,"stand_first":"In a report, the Health Services Safety Investigations Body recommends that hospitals evaluate their processes so that patients in need of time-critical medicines are identified as soon as possible upon admission.","stand_first_render_panel":true,"footnotes":""},"article_tag":[],"section":[27],"news-type":[69],"news-theme":[78,81],"location":[],"career-stage":[],"learning-theme":[],"condition-treatment":[],"career-development":[],"subject":[703,220,459,716,296,335],"class_list":["post-340358","news","type-news","status-publish","has-post-thumbnail","hentry","section-news","news-type-latest-news","news-theme-hospital","news-theme-medicines-safety","subject-clinical-pharmacy","subject-dispensing","subject-hospital-pharmacy","subject-parkinsons-disease","subject-pharmacy-sectors","subject-urgent-and-emergency-care"],"citation":{"data":{"publication":"The Pharmaceutical Journal","issue":"PJ, December 2024, Vol 313, No 7992","location":"313(7992):","doi":"10.1211\/PJ.2024.1.340358"},"rendered":"<i>The Pharmaceutical Journal<\/i>, PJ, December 2024, Vol 313, No 7992;313(7992)::DOI:10.1211\/PJ.2024.1.340358"},"article_extra":{"featured_image":{"src":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1985507219-927x617.jpg","sizes":{"small":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1985507219-469x312.jpg 469w","medium":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1985507219-650x433.jpg 650w","large":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1985507219-927x617.jpg 927w","xlarge":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1985507219-728x485.jpg 728w","retina":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1985507219-1456x967.jpg 1456w"},"alt_text":"","caption":"The report follows the death of a patient with Parkinson\u2019s disease who was not given doses of time-critical medicines after being admitted to hospital","source_credit":"Shutterstock.com"},"standfirst":"In a report, the Health Services Safety Investigations Body recommends that hospitals evaluate their processes so that patients in need of time-critical medicines are identified as soon as possible upon admission.","references":[],"authors":[{"name":"Corrinne Burns","image":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2021\/01\/1705-40x40.jpg","link":"https:\/\/pharmaceutical-journal.com\/author\/corrinne-burns"}],"corresponding_authors":[],"is_promotional":false,"is_supported":false,"is_sponsored":false,"badge":"","article_excerpt":"In a report, the Health Services Safety Investigations Body recommends that hospitals evaluate their processes so that patients in need of time-critical medicines are identified as soon as possible upon admission.…","content_partners":[],"modified_datetime":"10 December 2024 12:23 pm","quiz":[]},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Hospitals should review pharmacy support in emergency departments, says health safety investigation body - The Pharmaceutical Journal<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hospitals should review pharmacy support in emergency departments, says health safety investigation body\" \/>\n<meta property=\"og:description\" content=\"Hospitals should look at the pharmacy support available to staff in emergency departments, a report from the Health Services Safety Investigations Body (HSSIB) has said. The recommendation is from a report that was produced in response to the death of a patient with Parkinson’s disease, who was admitted to an unidentified hospital and spent three […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body\" \/>\n<meta property=\"og:site_name\" content=\"The Pharmaceutical Journal\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/PharmaceuticalJournal\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-10T12:23:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1985507219-scaled-e1733832156109.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@PJOnline_News\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body\",\"url\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body\",\"name\":\"Hospitals should review pharmacy support in emergency departments, says health safety investigation body - The Pharmaceutical Journal\",\"isPartOf\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1985507219-scaled-e1733832156109.jpg\",\"datePublished\":\"2024-12-10T12:23:20+00:00\",\"dateModified\":\"2024-12-10T12:23:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body#primaryimage\",\"url\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1985507219-scaled-e1733832156109.jpg\",\"contentUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1985507219-scaled-e1733832156109.jpg\",\"width\":1024,\"height\":576,\"caption\":\"The report follows the death of a patient with Parkinson\u2019s disease who was not given doses of time-critical medicines after being admitted to hospital\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pharmaceutical-journal.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/pharmaceutical-journal.com\/article\/news\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Hospitals should review pharmacy support in emergency departments, says health safety investigation body\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\",\"url\":\"https:\/\/pharmaceutical-journal.com\/\",\"name\":\"The Pharmaceutical Journal\",\"description\":\"The Pharmaceutical Journal from the Royal Pharmaceutical Society\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hospitals should review pharmacy support in emergency departments, says health safety investigation body - The Pharmaceutical Journal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body","og_locale":"en_US","og_type":"article","og_title":"Hospitals should review pharmacy support in emergency departments, says health safety investigation body","og_description":"Hospitals should look at the pharmacy support available to staff in emergency departments, a report from the Health Services Safety Investigations Body (HSSIB) has said. The recommendation is from a report that was produced in response to the death of a patient with Parkinson’s disease, who was admitted to an unidentified hospital and spent three […]","og_url":"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body","og_site_name":"The Pharmaceutical Journal","article_publisher":"https:\/\/www.facebook.com\/PharmaceuticalJournal","article_modified_time":"2024-12-10T12:23:22+00:00","og_image":[{"width":1024,"height":576,"url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1985507219-scaled-e1733832156109.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@PJOnline_News","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body","url":"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body","name":"Hospitals should review pharmacy support in emergency departments, says health safety investigation body - The Pharmaceutical Journal","isPartOf":{"@id":"https:\/\/pharmaceutical-journal.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body#primaryimage"},"image":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body#primaryimage"},"thumbnailUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1985507219-scaled-e1733832156109.jpg","datePublished":"2024-12-10T12:23:20+00:00","dateModified":"2024-12-10T12:23:22+00:00","breadcrumb":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body#primaryimage","url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1985507219-scaled-e1733832156109.jpg","contentUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/shutterstock_1985507219-scaled-e1733832156109.jpg","width":1024,"height":576,"caption":"The report follows the death of a patient with Parkinson\u2019s disease who was not given doses of time-critical medicines after being admitted to hospital"},{"@type":"BreadcrumbList","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/acute-hospitals-should-review-pharmacy-support-in-emergency-departments-says-health-safety-investigation-body#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pharmaceutical-journal.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/pharmaceutical-journal.com\/article\/news"},{"@type":"ListItem","position":3,"name":"Hospitals should review pharmacy support in emergency departments, says health safety investigation body"}]},{"@type":"WebSite","@id":"https:\/\/pharmaceutical-journal.com\/#website","url":"https:\/\/pharmaceutical-journal.com\/","name":"The Pharmaceutical Journal","description":"The Pharmaceutical Journal from the Royal Pharmaceutical Society","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340358"}],"collection":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/types\/news"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/comments?post=340358"}],"version-history":[{"count":4,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340358\/revisions"}],"predecessor-version":[{"id":340619,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340358\/revisions\/340619"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media\/340502"}],"wp:attachment":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media?parent=340358"}],"wp:term":[{"taxonomy":"article_tag","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/article_tag?post=340358"},{"taxonomy":"section","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/section?post=340358"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-type?post=340358"},{"taxonomy":"news-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-theme?post=340358"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/location?post=340358"},{"taxonomy":"career-stage","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-stage?post=340358"},{"taxonomy":"learning-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/learning-theme?post=340358"},{"taxonomy":"condition-treatment","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/condition-treatment?post=340358"},{"taxonomy":"career-development","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-development?post=340358"},{"taxonomy":"subject","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/subject?post=340358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":340434,"date":"2024-12-09T16:00:26","date_gmt":"2024-12-09T16:00:26","guid":{"rendered":"https:\/\/pharmaceutical-journal.com\/?post_type=news&p=340434"},"modified":"2024-12-09T16:31:46","modified_gmt":"2024-12-09T16:31:46","slug":"nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england","status":"publish","type":"news","link":"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england","title":{"rendered":"NHS data show significant variation in GP referrals to Pharmacy First across England"},"content":{"rendered":"<p>The number of GP referrals to the Pharmacy First clinical pathway\u00a0service in England has varied widely between integrated care boards (ICBs), NHS England data have shown.<\/p><p>The data, obtained by <em>The Pharmaceutical Journal<\/em> following a freedom of information request to NHS England, revealed that GPs made a total of 167,497 referrals to community pharmacy for Pharmacy First between 31 January and 30 September 2024,.<\/p><p>However, the volume of referrals varied between ICBs, with GPs in NHS Greater Manchester ICB making 11,683 referrals, while 612 referrals were made in NHS Cornwall and the Isles of Scilly ICB.<\/p><p>The <a href=\"\/article\/feature\/a-mammoth-undertaking-opening-the-doors-to-pharmacy-first\">Pharmacy First clinical pathway service, which launched on 31 January 2024<\/a>, provides treatment in community pharmacies for seven common conditions and offers community pharmacies a \u00a315 fee per consultation.<\/p><p>The data from NHS England only include referrals that led to consultations that were completed and claimed for by pharmacists and do not include referrals where the patient did not attend or the consultation was not completed \u2014 for instance if a clinical pathway outcome was not reached.<\/p><p>Pharmacists have not yet claimed for all activity undertaken during August and September 2024.<\/p><p>When accounting for the population in each ICB, the data show GPs in NHS North West London ICB made the fewest referrals per 100,000 people at 65 referrals (see Figure).<\/p><p>Meanwhile, GPs in NHS Bristol, North Somerset and South Gloucestershire ICB made the highest number of referrals at 939 per 100,000 people.<\/p><div class=\"flourish-embed flourish-map\" data-src=\"visualisation\/20696343?1506918\"><script src=\"\nhttps:\/\/public.flourish.studio\/resources\/embed.js\"><\/script><noscript><img\nsrc=\"\nhttps:\/\/public.flourish.studio\/visualisation\/20696343\/thumbnail\"\nwidth=\"100%\" alt=\"map visualization\" \/><\/noscript><\/div><p>NHS England has not previously released data on GP referrals to the Pharmacy First service.<\/p><p>However, the NHS\u2019s 2024\u00a0GP Patient Survey revealed in July 2024 that of the 515,642 respondents in England, <a href=\"\/article\/news\/nhs-survey-reveals-fewer-than-5-of-patients-have-been-referred-to-community-pharmacy-from-general-practice\">fewer than 5% were referred to community pharmacy by their GP practice<\/a>.<\/p><p>A spokesperson for NHS Norfolk and Waveney ICB, which had one of the lowest rates of GP referrals per 100,000 people at 71 referrals, said the ICB recognised that \u201cGP referrals to the Pharmacy First service in Norfolk and Waveney are lower than some areas\u201d.<\/p><p>\u201cMany referrals do happen through verbal signposting though, and these aren\u2019t reflected in the figures,\u201d they said, adding that the ICB is actively working to improve integration and will shortly be launching a GP toolkit to support the promotion of Pharmacy First.<\/p><p>Alison Mundell, community pharmacy clinical lead at Bristol, North Somerset and South Gloucestershire ICB, said that the ICB and Community Pharmacy Avon (CPA) had worked closely together to support surgeries in feeling confident about referring to Pharmacy First.<\/p><p>\u201cCPA has provided one-to-one surgery support to ensure surgeries understand the scope of clinical practice the pharmacies can support, which has in turn led to the pharmacies being able to support and treat a greater proportion of patients,\u201d she said.<\/p><p>Commenting on the NHS data, Alastair Buxton, director of NHS services at Community Pharmacy England, said: \u201cThe variability in GP referrals to Pharmacy First across the country is a matter of ongoing concern for us.\u201d<\/p><p>Buxton added that it was \u201cunhelpful and disappointing that so many practices are choosing to signpost patients to pharmacies, rather than making formal referrals,\u201d noting that there is still significant scope for many more referrals to be made from general practices to the Pharmacy First service.<\/p><p>Malcolm Harrison, chief executive of the Company Chemists\u2019 Association, said: \u201cIt\u2019s clear that all ICBs can do more to drive Pharmacy First activity. The opportunity to free up GP capacity at a critical time for the NHS is one that must not be missed.\u201d<\/p><p>Kamila Hawthorne, chair of the Royal College of GPs, told <em>The Pharmaceutical Journal<\/em> that it would be \u201cuseful to see further exploration as to whether there are barriers for practices in certain ICBs looking to engage with the scheme and how these can be overcome\u201d.<\/p><p>\u201cThe Pharmacy First scheme has the potential to support GPs and provide patients with a convenient pathway to care. But its success hinges on proper implementation, which includes having the right IT systems in place, as well as adequate training for both GP and pharmacy teams,” she added.<\/p><p>A spokesperson for NHS England said that the introduction of the Pharmacy First service \u201cmarks a significant expansion\u201d in the offering from pharmacies \u201cwith hundreds of thousands of consultations already delivered since its launch\u201d.<\/p><figure class=\"wp-block-embed is-type-rich is-provider-spotify wp-block-embed-spotify\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Spotify Embed: Spotlight: Safety of time-critical medicines\" style=\"border-radius: 12px\" width=\"100%\" height=\"152\" frameborder=\"0\" allowfullscreen allow=\"autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture\" loading=\"lazy\" src=\"https:\/\/open.spotify.com\/embed\/episode\/1yaebHLknS3mXDHFt4Xyci?utm_source=oembed\"><\/iframe>\n<\/div><\/figure>","protected":false},"excerpt":{"rendered":"<p>The number of GP referrals to the Pharmacy First clinical pathway\u00a0service in England has varied widely between integrated care boards (ICBs), NHS England data have shown. The data, obtained by The Pharmaceutical Journal following a freedom of information request to NHS England, revealed that GPs made a total of 167,497 referrals to community pharmacy for […]<\/p>\n","protected":false},"featured_media":340447,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"content_for_healthcare_professional":false,"catchline":"Community pharmacy services","featured_content_is_featured":false,"display_featured_image":true,"display_featured_image_as_hero":false,"_ml_titleColor":"#000000","_ml_titleFont":"Roboto","_ml_titleFontSize":1.136,"_ml_titleFontWeight":"400","_ml_titleLineHeight":1.3,"_ml_metaColor":"#708090","_ml_metaFont":"Montserrat","_ml_metaFontSize":0.6785,"_ml_metaFontWeight":"400","_ml_metaLineHeight":0.92,"_ml_bodyColor":"#a9a9a9","_ml_bodyFont":"Open Sans","_ml_bodyFontSize":0.85,"_ml_bodyFontWeight":"400","_ml_bodyLineHeight":1.2,"_ml_wooPriceColor":"#666","_ml_wooPriceFont":"Open Sans","_ml_wooPriceFontSize":0.9,"_ml_wooPriceFontWeight":"400","_ml_wooPriceLineHeight":1.27,"_ml_headingColor":"#000","_ml_headingFont":"Merriweather","_ml_headingFontSize":2.02,"_ml_headingFontWeight":"700","_ml_headingLineHeight":1.47,"_mlglobal_userfontcolors":{"headingColorUser":[],"titleColorUser":[],"metaColorUser":[],"bodyColorUser":[],"wooPriceColorUser":[]},"_oasis_is_in_workflow":0,"_oasis_original":0,"_oasis_task_priority":"2normal","premium_content_is_premium":"yes","premium_content_render_panel":true,"stand_first":"Exclusive: GPs in one integrated care board area made more than 11,000 Pharmacy First referrals between 31 January and 30 September 2024, while in another the figure was lower than 650.","stand_first_render_panel":true,"footnotes":""},"article_tag":[],"section":[27],"news-type":[69],"news-theme":[77],"location":[],"career-stage":[],"learning-theme":[],"condition-treatment":[],"career-development":[],"subject":[402,208,651,175,177,324],"class_list":["post-340434","news","type-news","status-publish","has-post-thumbnail","hentry","section-news","news-type-latest-news","news-theme-community","subject-community-pharmacy","subject-community-pharmacy-services","subject-nhs-england","subject-pharmacy-practice","subject-research-and-evaluation","subject-society-law-and-politics"],"citation":{"data":{"publication":"The Pharmaceutical Journal","issue":"PJ, December 2024, Vol 313, No 7992","location":"313(7992):","doi":"10.1211\/PJ.2024.1.340434"},"rendered":"<i>The Pharmaceutical Journal<\/i>, PJ, December 2024, Vol 313, No 7992;313(7992)::DOI:10.1211\/PJ.2024.1.340434"},"article_extra":{"featured_image":{"src":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/PharmacyFirstreferral-927x617.jpg","sizes":{"small":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/PharmacyFirstreferral-469x312.jpg 469w","medium":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/PharmacyFirstreferral-650x433.jpg 650w","large":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/PharmacyFirstreferral-927x617.jpg 927w","xlarge":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/PharmacyFirstreferral-728x485.jpg 728w","retina":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/PharmacyFirstreferral-1456x967.jpg 1456w"},"alt_text":"Woman has ear checked by healthcare professional","caption":"GP referrals varied from 65 per 100,000 population in one part of the country to 939 in a different area","source_credit":"Shutterstock.com"},"standfirst":"Exclusive: GPs in one integrated care board area made more than 11,000 Pharmacy First referrals between 31 January and 30 September 2024, while in another the figure was lower than 650.","references":[],"authors":[{"name":"Dawn Connelly","image":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2021\/01\/443-40x40.jpg","link":"https:\/\/pharmaceutical-journal.com\/author\/dawn-connelly"}],"corresponding_authors":[],"is_promotional":false,"is_supported":false,"is_sponsored":false,"badge":"","article_excerpt":"Exclusive: GPs in one integrated care board area made more than 11,000 Pharmacy First referrals between 31 January and 30 September 2024, while in another the figure was lower than 650.…","content_partners":[],"modified_datetime":"9 December 2024 4:31 pm","quiz":[]},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NHS data show significant variation in GP referrals to Pharmacy First across England - The Pharmaceutical Journal<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NHS data show significant variation in GP referrals to Pharmacy First across England\" \/>\n<meta property=\"og:description\" content=\"The number of GP referrals to the Pharmacy First clinical pathway\u00a0service in England has varied widely between integrated care boards (ICBs), NHS England data have shown. The data, obtained by The Pharmaceutical Journal following a freedom of information request to NHS England, revealed that GPs made a total of 167,497 referrals to community pharmacy for […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england\" \/>\n<meta property=\"og:site_name\" content=\"The Pharmaceutical Journal\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/PharmaceuticalJournal\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-09T16:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/PharmacyFirstreferral-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1702\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@PJOnline_News\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england\",\"url\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england\",\"name\":\"NHS data show significant variation in GP referrals to Pharmacy First across England - The Pharmaceutical Journal\",\"isPartOf\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/PharmacyFirstreferral-scaled.jpg\",\"datePublished\":\"2024-12-09T16:00:26+00:00\",\"dateModified\":\"2024-12-09T16:31:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england#primaryimage\",\"url\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/PharmacyFirstreferral-scaled.jpg\",\"contentUrl\":\"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/PharmacyFirstreferral-scaled.jpg\",\"width\":2560,\"height\":1702,\"caption\":\"GP referrals varied from 65 per 100,000 population in one part of the country to 939 in a different area\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pharmaceutical-journal.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/pharmaceutical-journal.com\/article\/news\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"NHS data show significant variation in GP referrals to Pharmacy First across England\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pharmaceutical-journal.com\/#website\",\"url\":\"https:\/\/pharmaceutical-journal.com\/\",\"name\":\"The Pharmaceutical Journal\",\"description\":\"The Pharmaceutical Journal from the Royal Pharmaceutical Society\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NHS data show significant variation in GP referrals to Pharmacy First across England - The Pharmaceutical Journal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england","og_locale":"en_US","og_type":"article","og_title":"NHS data show significant variation in GP referrals to Pharmacy First across England","og_description":"The number of GP referrals to the Pharmacy First clinical pathway\u00a0service in England has varied widely between integrated care boards (ICBs), NHS England data have shown. The data, obtained by The Pharmaceutical Journal following a freedom of information request to NHS England, revealed that GPs made a total of 167,497 referrals to community pharmacy for […]","og_url":"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england","og_site_name":"The Pharmaceutical Journal","article_publisher":"https:\/\/www.facebook.com\/PharmaceuticalJournal","article_modified_time":"2024-12-09T16:31:46+00:00","og_image":[{"width":2560,"height":1702,"url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/PharmacyFirstreferral-scaled.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@PJOnline_News","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england","url":"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england","name":"NHS data show significant variation in GP referrals to Pharmacy First across England - The Pharmaceutical Journal","isPartOf":{"@id":"https:\/\/pharmaceutical-journal.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england#primaryimage"},"image":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england#primaryimage"},"thumbnailUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/PharmacyFirstreferral-scaled.jpg","datePublished":"2024-12-09T16:00:26+00:00","dateModified":"2024-12-09T16:31:46+00:00","breadcrumb":{"@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england#primaryimage","url":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/PharmacyFirstreferral-scaled.jpg","contentUrl":"https:\/\/pharmaceutical-journal.com\/wp-content\/uploads\/2024\/12\/PharmacyFirstreferral-scaled.jpg","width":2560,"height":1702,"caption":"GP referrals varied from 65 per 100,000 population in one part of the country to 939 in a different area"},{"@type":"BreadcrumbList","@id":"https:\/\/pharmaceutical-journal.com\/article\/news\/nhs-data-show-significant-variation-in-gp-referrals-to-pharmacy-first-across-england#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pharmaceutical-journal.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/pharmaceutical-journal.com\/article\/news"},{"@type":"ListItem","position":3,"name":"NHS data show significant variation in GP referrals to Pharmacy First across England"}]},{"@type":"WebSite","@id":"https:\/\/pharmaceutical-journal.com\/#website","url":"https:\/\/pharmaceutical-journal.com\/","name":"The Pharmaceutical Journal","description":"The Pharmaceutical Journal from the Royal Pharmaceutical Society","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharmaceutical-journal.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340434"}],"collection":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/types\/news"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/comments?post=340434"}],"version-history":[{"count":5,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340434\/revisions"}],"predecessor-version":[{"id":340496,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news\/340434\/revisions\/340496"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media\/340447"}],"wp:attachment":[{"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/media?parent=340434"}],"wp:term":[{"taxonomy":"article_tag","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/article_tag?post=340434"},{"taxonomy":"section","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/section?post=340434"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-type?post=340434"},{"taxonomy":"news-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/news-theme?post=340434"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/location?post=340434"},{"taxonomy":"career-stage","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-stage?post=340434"},{"taxonomy":"learning-theme","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/learning-theme?post=340434"},{"taxonomy":"condition-treatment","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/condition-treatment?post=340434"},{"taxonomy":"career-development","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/career-development?post=340434"},{"taxonomy":"subject","embeddable":true,"href":"https:\/\/pharmaceutical-journal.com\/wp-json\/wp\/v2\/subject?post=340434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}]